<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer - Patel, A - 2022 | Cochrane Library</title> <meta content="Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer - Patel, A - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008766.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer - Patel, A - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008766.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008766.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer" name="citation_title"/> <meta content="Aashna Patel" name="citation_author"/> <meta content="Middlesex University" name="citation_author_institution"/> <meta content="Roshni Kalachand" name="citation_author"/> <meta content="Beaumont Hospital and Royal College of Surgeons in Ireland" name="citation_author_institution"/> <meta content="Steven Busschots" name="citation_author"/> <meta content="St James Hospital and Trinity College Dublin" name="citation_author_institution"/> <meta content="Ben Doherty" name="citation_author"/> <meta content="St James Hospital and Trinity College Dublin" name="citation_author_institution"/> <meta content="Evangelos Kapros" name="citation_author"/> <meta content="Trinity College Dublin" name="citation_author_institution"/> <meta content="Denise Lawlor" name="citation_author"/> <meta content="St James Hospital and Trinity College Dublin" name="citation_author_institution"/> <meta content="Neville Hall" name="citation_author"/> <meta content="Middlesex University" name="citation_author_institution"/> <meta content="Britta K Stordal" name="citation_author"/> <meta content="Middlesex University" name="citation_author_institution"/> <meta content="b.stordal@mdx.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD008766.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/07/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008766.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008766.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008766.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alopecia [drug therapy]; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial [drug therapy]; Neoplasm Recurrence, Local [drug therapy]; *Neutropenia; *Ovarian Neoplasms [drug therapy]; Paclitaxel [adverse effects]; Taxoids [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008766.pub3&amp;doi=10.1002/14651858.CD008766.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="jxlIh5Me";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008766\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008766\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","th","pt","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008766.pub3",title:"Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer",firstPublishedDate:"Jul 12, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008766.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008766.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008766.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008766.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008766.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008766.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008766.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008766.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008766.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008766.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2377 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008766.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-sec-0111"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-sec-0092"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/appendices#CD008766-sec-0116"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/supinfo/CD008766StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/supinfo/CD008766StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information#CD008766-cr-0004">Aashna Patel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information#CD008766-cr-0005">Roshni Kalachand</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information#CD008766-cr-0006">Steven Busschots</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information#CD008766-cr-0007">Ben Doherty</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information#CD008766-cr-0008">Evangelos Kapros</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information#CD008766-cr-0009">Denise Lawlor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information#CD008766-cr-0010">Neville Hall</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information#CD008766-cr-0011"><i class="icon corresponding-author fa fa-envelope"></i>Britta K Stordal</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information/en#CD008766-sec-0123">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 July 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008766.pub3">https://doi.org/10.1002/14651858.CD008766.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008766-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008766-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008766-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008766-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008766-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008766-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD008766-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008766-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008766-abs-0001" lang="en"> <section id="CD008766-sec-0001"> <h3 class="title" id="CD008766-sec-0001">Background</h3> <p>Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most common kind, accounting for 90% of cases. First‐line therapy for women with epithelial ovarian cancer consists of a combination of cytoreductive surgery and platinum and taxane‐based chemotherapy. However, more than 50% of women with epithelial ovarian cancer will experience a relapse and require further chemotherapy and at some point develop resistance to platinum‐based drugs. </p> <p>Currently, guidance on the use of most chemotherapy drugs, including taxanes, is unclear for women whose epithelial ovarian cancer has recurred. Paclitaxel, topotecan, pegylated liposomal doxorubicin hydrochloride, trabectedin and gemcitabine are all licensed for use in the UK at the discretion of clinicians, following discussion with the women as to potential adverse effects. Taxanes can be given in once‐weekly regimens (at a lower dose) or three‐weekly regimens (at a higher dose), which may have differences in the severity of side effects and effectiveness. As relapsed disease suggests incurable disease, it is all the more important to consider side effects and the impact of treatment schedules, as well as quality of life, and not only the life‐prolonging effects of treatment. </p> </section> <section id="CD008766-sec-0002"> <h3 class="title" id="CD008766-sec-0002">Objectives</h3> <p>To assess the efficacy and toxicity of different taxane monotherapy regimens for women with recurrent epithelial ovarian, tubal or primary peritoneal cancer. </p> </section> <section id="CD008766-sec-0003"> <h3 class="title" id="CD008766-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE and Embase, up to 22 March 2022. Other related databases and trial registries were searched as well as grey literature and no additional studies were identified. A total of 1500 records were identified. </p> </section> <section id="CD008766-sec-0004"> <h3 class="title" id="CD008766-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials of taxane monotherapy for adult women diagnosed with recurrent epithelial ovarian, tubal or primary peritoneal cancer, previously treated with platinum‐based chemotherapy. We included trials comparing two or more taxane monotherapy regimens. Participants could be experiencing their first recurrence of disease or any line of recurrence. </p> </section> <section id="CD008766-sec-0005"> <h3 class="title" id="CD008766-sec-0005">Data collection and analysis</h3> <p>Two review authors screened, independently assessed studies, and extracted data from the included studies. The clinical outcomes we examined were overall survival, response rate, progression‐free survival, neurotoxicity, neutropenia, alopecia, and quality of life. We performed statistical analyses using fixed‐effect and random‐effects models following standard Cochrane methodology. We rated the certainty of evidence according to the GRADE approach. </p> </section> <section id="CD008766-sec-0006"> <h3 class="title" id="CD008766-sec-0006">Main results</h3> <p>Our literature search yielded 1500 records of 1466 studies; no additional studies were identified by searching grey literature or handsearching. We uploaded the search results into Covidence. After the exclusion of 92 duplicates, we screened titles and abstracts of 1374 records. Of these, we identified 24 studies for full‐text screening. We included four parallel‐group randomised controlled trials (RCTs). All trials were multicentred and conducted in a hospital setting. The studies included 981 eligible participants with recurrent epithelial ovarian cancer, tubal or primary peritoneal cancer with a median age ranging between 56 to 62 years of age. All participants had a WHO (World Health Organization) performance status of between 0 to 2. The proportion of participants with serous histology ranged between 56% to 85%. Participants included women who had platinum‐sensitive (71%) and platinum‐resistant (29%) relapse. Some participants were taxane pre‐treated (5.6%), whilst the majority were taxane‐naive (94.4%). No studies were classified as having a high risk of bias for any of the domains in the Cochrane risk of bias tool. </p> <p>We found that there may be little or no difference in overall survival (OS) between weekly paclitaxel and three‐weekly paclitaxel, but the evidence is very uncertain (risk ratio (RR) of 0.94, 95% confidence interval (CI) 0.66 to 1.33, two studies, 263 participants, very low‐certainty evidence). Similarly, there may be little or no difference in response rate (RR of 1.07, 95% CI 0.78 to 1.48, two studies, 263 participants, very low‐certainty evidence) and progression‐free survival (PFS) (RR of 0.83, 95% CI 0.46 to 1.52, two studies, 263 participants, very low‐certainty evidence) between weekly and three‐weekly paclitaxel, but the evidence is very uncertain. </p> <p>We found differences in the chemotherapy‐associated adverse events between the weekly and three‐weekly paclitaxel regimens. The weekly paclitaxel regimen may result in a reduction in neutropenia (RR 0.51, 95% 0.27 to 0.95, two studies, 260 participants, low‐certainty evidence) and alopecia (RR 0.58, 95% CI 0.46 to 0.73, one study, 205 participants, low‐certainty evidence). There may be little or no difference in neurotoxicity, but the evidence was very low‐certainty and we cannot exclude an effect (RR 0.53, 95% CI 0.19 to 1.45, two studies, 260 participants). </p> <p>When examining the effect of paclitaxel dosage in the three‐weekly regimen, the 250 mg/m<sup>2</sup> paclitaxel regimen probably causes more neurotoxicity compared to the 175 mg/m<sup>2</sup> regimen (RR 0.41, 95% CI 0.21 to 0.80, one study, 330 participants, moderate‐certainty evidence). </p> <p>Quality‐of‐life data were not extractable from any of the included studies.</p> </section> <section id="CD008766-sec-0007"> <h3 class="title" id="CD008766-sec-0007">Authors' conclusions</h3> <p>Fewer people may experience neutropenia when given weekly rather than three‐weekly paclitaxel (low‐certainty evidence), although it may make little or no difference to the risk of developing neurotoxicity (very low‐certainty evidence). This is based on the participants receiving lower doses of drug more often. However, our confidence in this result is low and the true effect may be substantially different from the estimate of the effect. Weekly paclitaxel probably reduces the risk of alopecia, although the rates in both arms were high (46% versus 79%) (low‐certainty evidence). A change to weekly from three‐weekly chemotherapy could be considered to reduce the likelihood of toxicity, as it may have little or no negative impact on response rate (very low‐certainty evidence), PFS (very low‐certainty evidence) or OS (very low‐certainty evidence). </p> <p>Three‐weekly paclitaxel, given at a dose of 175 mg/m<sup>2</sup> compared to a higher dose,probably reduces the risk of neurotoxicity.We are moderately confident in this result; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. A change to 175 mg/m<sup>2</sup> paclitaxel (from a higher dose), if a three‐weekly regimen is used, probably has little or no negative impact on PFS or OS (very low‐certainty evidence). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008766-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008766-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008766-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008766-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008766-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008766-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008766-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008766-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008766-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD008766-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008766-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008766-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008766-abs-0002" lang="en"> <h3>How should we give taxane as a single chemotherapy agent to women with relapsed epithelial ovarian cancer? </h3> <p><b>Background</b><br/>There are a variety of options for chemotherapy treatment of relapsed epithelial ovarian cancer. Decisions at relapse include not just what drug, but also what dose and timing of administration. Taxanes can be given in once‐weekly (at a lower dose) or three‐weekly (at a higher dose) regimens, which may lead to differences in the severity of side effects and effectiveness. As relapsed disease suggests incurable disease; it is all the more important to consider side effects and the impact of treatment schedules, as well as quality of life, and not only the life‐prolonging effects of treatment. </p> <p><b>Objectives</b><br/>To assess the benefits and side effects of different treatment intervals and different doses of taxane chemotherapy for women with relapsed epithelial ovarian cancer. </p> <p><b>Methods</b><br/>We included randomised‐controlled trials (RCTs) (clinical studies where people are randomly put into one of two or more treatment groups) of two or more taxane treatments for women with relapsed epithelial ovarian cancer. The clinical outcomes we examined were: 1) overall survival ‐ how long a participant survives after their diagnosis; 2) response rate ‐ how many participants have scan or blood test evidence that their ovarian cancer reduces in size in response to chemotherapy; 3) progression‐free survival ‐ the amount of time a participant lives with the disease without evidence of it continuing to grow; 4) neurotoxicity ‐ how many participants experienced nerve damage leading to sensory or motor co‐ordination problems, usually in their hands and feet; 5) neutropenia ‐ how many participants experienced a dangerous drop in white blood cells (neutrophils) which can lead to infection; 6) alopecia ‐ how many participants experienced high levels of hair loss; 7) quality of life ‐ a measure of the overall impact of the disease and treatment on the participants' daily life; this is recorded by a questionnaire. </p> <p>We performed statistical analyses following Cochrane methodology.</p> <p><b>Results</b><br/>We included four RCTs which we assessed as being at low risk of bias, i.e. the results are likely to be a fair reflection of the differences between the groups studied. These studies included data for 981 women who had relapsed epithelial ovarian cancer. </p> <p><b>Weekly versus three‐weekly taxane treatment</b><br/>We found that there are probably few or no differences in how long women survived after treatment and there may be little or no difference in how long it took for their cancers to re‐grow if taxanes were given weekly or three‐weekly. There may be little or no difference in the number of women who had evidence of their cancer shrinking in response to taxane treatment if given weekly or three‐weekly. </p> <p>However, we found that there were probably differences in the side effects between the weekly and three‐weekly regimens. Women probably experienced more severe hair loss (alopecia) and may be more likely to have neutropenia (a lower level of white blood cells, which can lead to infections) in the three‐weekly paclitaxel treatment compared to a lower dose of taxane given more frequently with weekly treatment. There may or may not be an increased risk of neurotoxicity (nerve damage) with three‐weekly paclitaxel when given at a higher dose, but we have low certainty about this result. </p> <p><b>Different doses of taxane given three‐weekly</b><br/>Women who received a lower dose of taxane every three weeksprobably had less neurotoxicity and we have moderate certainty in this result. We found that there are probably few or no differences in how long women survived or how long it took for their cancer to progress after treatment between the groups. </p> <p><b>Conclusions</b><br/>Women who receive weekly paclitaxel probably have fewer side effects, as well as women who receive a lower dose three‐weekly. The change to either a lower dose every three weeks, or weekly scheduling of a lower dose, may make little or no difference in how long women survive after treatment. Weekly treatment may offer similar treatment effects with fewer side effects, albeit at the cost of more frequent hospital visits. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008766-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008766-sec-0111"></div> <h3 class="title" id="CD008766-sec-0112">Implications for practice</h3> <section id="CD008766-sec-0112"> <p>Weekly paclitaxel may result in a reduction in neutropenia and alopecia with little to no effect on response rate, progression‐free survival and overall survival (<a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>). Our confidence in these results is low; the true effect may be substantially different from the estimate of the effect (<a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>). However, numerous single‐arm studies are in agreement with these findings. </p> <p>Within the three‐weekly regimen, a lower dose of 175 mg/m<sup>2</sup> paclitaxel probably reduces neurotoxicity (<a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>). We are moderately confident in this effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different (<a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>). However, numerous single‐arm studies are in agreement with these findings. </p> <p>In order to reduce the adverse events experienced by participants, a shift to weekly paclitaxel could be considered, as well as dose reductions in the three‐weekly regimen, as it appears to have little to no effect on response rate, progression‐free survival or overall survival. </p> </section> <h3 class="title" id="CD008766-sec-0113">Implications for research</h3> <section id="CD008766-sec-0113"> <p>We have no evidence to suggest that participants' quality of life is improved by experiencing fewer adverse events, although this is a logical assumption. All the included studies in this review did not include quality‐of‐life data in an extractable format. Future clinical trials in this area, should present mean quality‐of‐life scores before and after chemotherapy and present these results in a clearly extractable format for each arm of a randomised controlled trial. </p> <p>We found no randomised controlled trials on docetaxel, so we can not make any recommendations as to the benefit of this agent compared to paclitaxel. There are many non‐randomised studies in the recurrent epithelial ovarian cancer setting. Investigators should shift to conducting small randomised studies so their results can be included in future Cochrane reviews to inform clinical practice. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008766-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008766-sec-0008"></div> <div class="table" id="CD008766-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Weekly paclitaxel compared to three‐weekly paclitaxel for the treatment of recurrent epithelial ovarian cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Weekly paclitaxel compared to three‐weekly paclitaxel for the treatment of recurrent epithelial ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with recurrent epithelial ovarian cancer<br/><b>Setting:</b> hospital or clinic<br/><b>Intervention:</b> weekly paclitaxel<br/><b>Comparison:</b> three‐weekly paclitaxel </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with three‐weekly paclitaxel</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with weekly paclitaxel</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival<br/>follow‐up: mean 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.94<br/>(0.66 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>263<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may have little to no effect on overall survival but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 100<br/>(63 to 87) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/>(0.78 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>263<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may have little to no effect on response rate but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 100<br/>(26 to 49) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate ‐ platinum‐sensitive</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/>(0.77 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may have little to no effect on response rate in platinum‐sensitive disease but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 100<br/>(37 to 79) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate ‐ platinum‐resistant</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.55 to 2.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>163<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may have little to no effect on response rate in platinum‐resistant disease but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 100<br/>(12 to 47) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of Life ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival<br/>follow‐up: mean 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.83<br/>(0.46 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>263<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,</sup><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may have little to no effect on progression‐free survival but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 100<br/>(100 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurotoxicity</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.53<br/>(0.19 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>260<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may have little to no effect on neurotoxicity but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 100<br/>(5 to 38) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neutropenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.51<br/>(0.27 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>260<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may result in a reduction in neutropenia.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 100<br/>(11 to 38) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Alopecia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.58<br/>(0.46 to 0.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>205<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may result in a reduction in alopecia.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 100<br/>(36 to 58) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 3 levels for extremely serious imprecision (fewer than 300 events, fewer than 5 studies and the 95% CI included both appreciable benefit and appreciable harm) </p> <p><sup>2</sup> Downgraded 1 level for inconsistency (moderate heterogeneity between the 2 included studies. Possibly due to taxane pre‐treatment status) </p> <p><sup>3</sup> Downgraded 2 levels for very serious imprecision (fewer than 300 events, and fewer than 5 studies) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008766-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">175 mg/m2 paclitaxel compared to 250 mg/m2 paclitaxel for the treatment of recurrent epithelial ovarian cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>175 mg/m<sup>2</sup> paclitaxel compared to 250 mg/m<sup>2</sup> paclitaxel for the treatment of recurrent epithelial ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with recurrent epithelial ovarian cancer<br/><b>Setting:</b> hospital or clinic<br/><b>Intervention:</b> 175 mg/m<sup>2</sup> paclitaxel<br/><b>Comparison:</b> 250 mg/m<sup>2</sup> paclitaxel </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 250 mg/m<sup>2</sup> paclitaxel</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 175 mg/m<sup>2</sup> paclitaxel</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival<br/>follow‐up: mean 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.97<br/>(0.77 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel may result in little to no difference in overall survival. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 100<br/>(77 to 90) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.40 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>265<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel may have little to no effect on response rate but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 100<br/>(15 to 69) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate ‐ platinum‐sensitive</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.60<br/>(0.39 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>213<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel may result in a reduction in response rate in platinum‐sensitive disease. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 100<br/>(14 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate ‐ platinum‐resistant</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.34<br/>(0.70 to 2.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel may have little to no effect on response rate in platinum‐resistant disease but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 100<br/>(25 to 93) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of Life ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival<br/>follow‐up: mean 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.07<br/>(0.88 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel may result in little to no difference in progression‐free survival. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>96 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 100<br/>(94 to 98) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurotoxicity</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.41<br/>(0.21 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel probably reduces neurotoxicity. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 100<br/>(3 to 13) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neutropenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/>(0.74 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel may result in little to no difference in neutropenia. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 100<br/>(14 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alopecia ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 2 levels for serious imprecision (fewer than 5 studies and 95% CI included both appreciable benefit and appreciable harm) </p> <p><sup>2</sup> Downgraded 3 levels for very serious imprecision (fewer than 300 events, fewer than 5 studies and 95% CI included both appreciable benefit and appreciable harm) </p> <p><sup>3</sup> Downgraded 2 levels for serious imprecision (fewer than 300 events, fewer than 5 studies) </p> <p><sup>4</sup> Downgraded 1 level for imprecision (fewer than 5 studies) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008766-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">135 mg/m2 paclitaxel compared to 175 mg/m2 paclitaxel for the treatment of recurrent epithelial ovarian cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>135 mg/m<sup>2</sup> paclitaxel compared to 175 mg/m<sup>2</sup> paclitaxel for the treatment of recurrent epithelial ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with recurrent epithelial ovarian cancer<br/><b>Setting:</b> hospital or clinic<br/><b>Intervention:</b> 135 mg/m<sup>2</sup> paclitaxel<br/><b>Comparison:</b> 175 mg/m<sup>2</sup> paclitaxel </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 175 mg/m<sup>2</sup> paclitaxel</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 135 mg/m<sup>2</sup> paclitaxel</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival<br/>follow‐up: mean 15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.96<br/>(0.77 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>407<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>135 mg/m<sup>2</sup> paclitaxel may result in little to no difference in overall survival. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 100<br/>(65 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.48 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>382<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>135 mg/m<sup>2</sup> paclitaxel may result in little to no difference in response rate. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 100<br/>(9 to 23) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of Life ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival<br/>follow‐up: mean 15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.09<br/>(0.94 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>407<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>135 mg/m<sup>2</sup> paclitaxel may result in little to no difference in progression‐free survival. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 100<br/>(93 to 97) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurotoxicity</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.19<br/>(0.01 to 3.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>391<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>135 mg/m<sup>2</sup> paclitaxel may result in little to no difference in neurotoxicity. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(0 to 42) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutropenia ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alopecia ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 2 levels for very serious imprecision (fewer than 5 studies, 95% CI included both appreciable benefit and appreciable harm) </p> <p><sup>2</sup> Downgraded 3 levels for extremely serious imprecision (fewer than 300 events, fewer than 5 studies and 95% CI included both appreciable benefit and appreciable harm) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008766-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008766-sec-0009"></div> <section id="CD008766-sec-0010"> <h3 class="title" id="CD008766-sec-0010">Description of the condition</h3> <p>There were 313,959 new cases of ovarian cancer worldwide in 2020, with 207,252 deaths (<a href="./references#CD008766-bbs2-0034" title="FerlayJ , ColombetM , SoerjomataramI , ParkinDM , PinerosM , ZnaorA , et al. Cancer statistics for the year 2020: an overview. International Journal of Cancer2021;149(4):778-89.">Ferlay 2021</a>). In the UK, there were around 7,400 cases (2015 to 2017) and 4,200 deaths (2016 to 2018) from ovarian cancer (<a href="./references#CD008766-bbs2-0023" title="Cancer Research UK. Cancer incidence statistics. cancerresearchuk.org/health-professional/cancer-statistics/incidence (accessed 9 April 2021).">Cancer Research UK</a>). A woman's risk of developing ovarian cancer before the age of 75 years is estimated to range from 0.5% in low‐ and middle‐income countries to 1% in high‐income countries (<a href="./references#CD008766-bbs2-0050" title="JemalA , BrayF , Center MM, FerlayJ , WardE , FormanD . Global cancer statistics. CA: a Cancer Journal for Clinicians2011;61:69-90.">Jemal 2011</a>). In Europe, almost two‐thirds of women with ovarian cancer die within five years after diagnosis (<a href="./references#CD008766-bbs2-0031" title="SantM , AareleidT , BerrinoF , Bielska LasotaM , CarliPM , FaivreJ , et al, EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990–94 – results and commentary. Annals of Oncology2003;14(Suppl 5):v61-118.">EUROCARE 2003</a>), largely because most are diagnosed when the cancer is already at an advanced stage (<a href="./references#CD008766-bbs2-0049" title="JemalA , SiegelR , WardE , HaoY , XuJ , MurrayT , et al. Cancer statistics. CA: a Cancer Journal for Clinicians2008;58(2):71-96.">Jemal 2008</a>). </p> <p>Ninety per cent of ovarian cancers are epithelial in origin (<a href="./references#CD008766-bbs2-0028" title="DesaiA , XuJ , AysolaK , QinY , OkoliC , HariprasadR , et al. Epithelial ovarian cancer: an overview. World Journal of Translational Medicine2014;3(1):1-8.">Desai 2014</a>), hence, the focus of this Cochrane review is on epithelial ovarian cancer. Within epithelial ovarian cancer, the most common subtype is serous, accounting for 75% of cases (<a href="./references#CD008766-bbs2-0028" title="DesaiA , XuJ , AysolaK , QinY , OkoliC , HariprasadR , et al. Epithelial ovarian cancer: an overview. World Journal of Translational Medicine2014;3(1):1-8.">Desai 2014</a>). The remaining subtypes are mucinous, endometrioid, clear cell and Brenner tumours (<a href="./references#CD008766-bbs2-0028" title="DesaiA , XuJ , AysolaK , QinY , OkoliC , HariprasadR , et al. Epithelial ovarian cancer: an overview. World Journal of Translational Medicine2014;3(1):1-8.">Desai 2014</a>) which were previously known as transitional cell tumours (<a href="./references#CD008766-bbs2-0067" title="Meinhold-HeerleinI , FotopoulouC , HarterP , KurzederC , MusteaA , WimbergerP , et al. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Archives of Gynecology and Obstetrics2016;293(4):695-700.">Meinhold‐Heerlein 2016</a>). There is now substantial convincing evidence in support of the fallopian tube epithelium as the source of the cell of origin of low‐ and high‐grade serous ovarian cancer (<a href="./references#CD008766-bbs2-0096" title="VangR , Shih Le-M, KurmanRJ . Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology2013;62(1):44-58.">Vang 2013</a>). Therefore, most newer clinical trials of epithelial ovarian cancer include women with fallopian tube and primary peritoneal cancers (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>) as they have all come from the same origin, the fallopian tube. The FIGO (International Federation of Gynecology and Obstetrics) staging system indicates how advanced a case of epithelial ovarian cancer is. In Stage I, the tumour is confined to the ovaries or fallopian tubes. In Stage II, the tumour involves one or both ovaries or fallopian tubes with extension into the pelvis. In Stage III, the tumour has spread to the peritoneum outside the pelvis and or metastasis to the retroperitoneal lymph nodes. In Stage IV, there are distant metastases beyond the peritoneum (<a href="./references#CD008766-bbs2-0101" title="ZeppernickF , Meinhold-HeerleinI . The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Archives of Gynecology and Obstetrics2014;290(5):839-42.">Zeppernick 2014</a>). Epithelial ovarian cancer is typically diagnosed at FIGO Stage III or IV when it has already metastasised, leading to an overall poor prognosis. </p> <p>First‐line therapy for women with epithelial ovarian cancer consists of a combination of cytoreductive surgery and platinum‐based chemotherapy. Paclitaxel became the preferred partner to platinum chemotherapy after successful clinical trials in 1996 (<a href="./references#CD008766-bbs2-0065" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6.">McGuire 1996</a>; <a href="./references#CD008766-bbs2-0098" title="VermorkenJB . The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer. International Journal of Gynecological Cancer2001;11 Suppl 1:21-30.">Vermorken 2001</a>); and it is estimated that, in the UK, 75% of women with epithelial ovarian cancer receive platinum‒paclitaxel front‐line therapy (<a href="./references#CD008766-bbs2-0069" title="NICE. Guidance on the use of paclitaxel in the treatment of ovarian cancer: Technology appraisal guidance [TA55] Published date: 22 January 2003 Last updated: 01 May 2005. www.nice.org.uk/guidance/ta55 (accessed prior to 12 June 2022).">NICE 2005</a>). The remaining 25% of women receive only a platinum agent for front‐line therapy, primarily due to concerns of greater toxicity with the combined platinum‒paclitaxel regimen (<a href="./references#CD008766-bbs2-0069" title="NICE. Guidance on the use of paclitaxel in the treatment of ovarian cancer: Technology appraisal guidance [TA55] Published date: 22 January 2003 Last updated: 01 May 2005. www.nice.org.uk/guidance/ta55 (accessed prior to 12 June 2022).">NICE 2005</a>). This approach achieves complete clinical remission in the majority of women; however, more than 50% will experience a relapse and require further chemotherapy (<a href="./references#CD008766-bbs2-0075" title="OzolsRF . Systemic therapy for ovarian cancer: current status and new treatments. Seminars in Oncology2006;33(2 Suppl 6):S3-11.">Ozols 2006</a>). The consensus indicates that women whose cancer progresses while being treated with platinum chemotherapy or within four weeks of the last platinum dose are classed as platinum‐refractory; women who relapse within six months of completing platinum‐based therapy are platinum‐resistant; those who relapse between six and 12 months are partially platinum‐sensitive; and those who relapse 12 or more months later are platinum‐sensitive (<a href="./references#CD008766-bbs2-0035" title="FriedlanderM , TrimbleE , TinkerA , AlbertsD , Avall-LundqvistE , BradyM , et al. Clinical trials in recurrent ovarian cancer. International Journal of Gynecological Cancer2011;21(4):771-5.">Friedlander 2011</a>). In general, those women who have platinum‐sensitive epithelial ovarian cancer have a much better prognosis than patients who experience an early, platinum‐resistant relapse (<a href="./references#CD008766-bbs2-0086" title="StordalB , PavlakisN , DaveyR . A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treatment Reviews2007;33(8):688-703.">Stordal 2007a</a>; <a href="./references#CD008766-bbs2-0087" title="StordalB , PavlakisN , DaveyR . Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treatment Reviews2007;33(4):347-57.">Stordal 2007b</a>). </p> <p>Olaparib is licensed for use in recurrent, platinum‐sensitive epithelial ovarian cancer in women with BRCA1/2 mutations (<a href="./references#CD008766-bbs2-0071" title="NICE. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Technology appraisal guidance [TA620]. www.nice.org.uk/guidance/ta620 (accessed prior to 12 June 2022).">NICE 2020</a>). There is currently no single agent recommended in the UK for the treatment of women with recurrent epithelial ovarian cancer who do not have a BRCA1/2 mutation. Paclitaxel, topotecan, pegylated liposomal doxorubicin hydrochloride, trabectedin and gemcitabine are all licensed for use as single agents at the discretion of clinicians, following discussion with the women as to potential side effects (<a href="./references#CD008766-bbs2-0069" title="NICE. Guidance on the use of paclitaxel in the treatment of ovarian cancer: Technology appraisal guidance [TA55] Published date: 22 January 2003 Last updated: 01 May 2005. www.nice.org.uk/guidance/ta55 (accessed prior to 12 June 2022).">NICE 2005</a>; <a href="./references#CD008766-bbs2-0070" title="NICE. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer: Technology appraisal guidance [TA389]. www.nice.org.uk/guidance/ta389 (accessed prior to 12 June 2022).">NICE 2016</a>). Paclitaxel, in combination with platinum or as monotherapy, is recommended as an option for treating recurrent epithelial ovarian cancer (<a href="./references#CD008766-bbs2-0070" title="NICE. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer: Technology appraisal guidance [TA389]. www.nice.org.uk/guidance/ta389 (accessed prior to 12 June 2022).">NICE 2016</a>). However, there is no guidance on the use of docetaxel in recurrent epithelial ovarian cancer. </p> </section> <section id="CD008766-sec-0011"> <h3 class="title" id="CD008766-sec-0011">Description of the intervention</h3> <p>When any cell divides, cancerous or normal, the DNA in the form of chromosomes are copied and then moved to opposite ends of the cell by a network of microtubules (<a href="./references#CD008766-bbs2-0020" title="AlbertsB , JohnsonA , LewisJ , RaffM , RobertsK , WalterP . Mitosis. In: Molecular Biology of the Cell. 4th edition. New York, US: Garland Science, 2002.">Alberts 2002</a>). These microtubules form or polymerise when needed and then disappear after the cell divides. Taxanes, of which two examples are paclitaxel and docetaxel, cause cytotoxicity within the cancer cell by binding to and stabilising polymerised microtubules and preventing cell division (<a href="./references#CD008766-bbs2-0051" title="JordanMA , WilsonL . Microtubules as a target for anticancer drugs. Nature Reviews. Cancer2004;4(4):253-65.">Jordan 2004</a>). Additionally, at low concentrations, both paclitaxel and docetaxel have been shown to be anti‐angiogenic (inhibiting the development of new blood vessels) in preclinical cell models (<a href="./references#CD008766-bbs2-0042" title="GrantDS , WilliamsTL , ZahaczewskyM , DickerAP . Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). International Journal of Cancer2003;104(1):121-9.">Grant 2003</a>; <a href="./references#CD008766-bbs2-0095" title="VaccaA , RibattiD , IurlaroM , MerchionneF , NicoB , RiaR , et al. Docetaxel versus paclitaxel for antiangiogenesis. Journal of Hematotherapy &amp; Stem Cell Research2002;11(1):103-18.">Vacca 2002</a>). </p> <p>Both paclitaxel and docetaxel are insoluble in water (<a href="./references#CD008766-bbs2-0099" title="VerweijJ , ClavelM , ChevalierB . Paclitaxel (taxol) and docetaxel (taxotere): not simply two of a kind. Annals of Oncology1994;5(6):495-505.">Verweij 1994</a>) and have clinical formulations to enable them to be administered intravenously. Both paclitaxel and docetaxel are metabolised in the liver and undergo biliary excretion; the majority of the taxane dose is excreted in faeces (<a href="./references#CD008766-bbs2-0038" title="GligorovJ , LotzJP . Preclinical pharmacology of the taxanes: implications of the differences. Oncologist2004;9(S2):3-8.">Gligorov 2004</a>). Paclitaxel exhibits non‐linear pharmacokinetics, whereas docetaxel is linear. The implication of non‐linear pharmacokinetics is that alterations in dose result in disproportionate increases in the area under the time concentration curve (AUC) and the peak plasma concentration (<a href="./references#CD008766-bbs2-0038" title="GligorovJ , LotzJP . Preclinical pharmacology of the taxanes: implications of the differences. Oncologist2004;9(S2):3-8.">Gligorov 2004</a>). </p> </section> <section id="CD008766-sec-0012"> <h3 class="title" id="CD008766-sec-0012">How the intervention might work</h3> <p>The majority of studies comparing paclitaxel to docetaxel in epithelial ovarian cancer have been first‐line studies in combination with platinum agents. These studies have shown similar efficacy between the two taxanes but different adverse effect profiles (<a href="./references#CD008766-bbs2-0047" title="HsuY , SoodAK , SoroskyJI . Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. American Journal of Clinical Oncology2004;27(1):14-8.">Hsu 2004</a>; <a href="./references#CD008766-bbs2-0097" title="VaseyPA , JaysonGC , GordonA , GabraH , ColemanR , AtkinsonR , et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute2004;96(22):1682-91.">Vasey 2004</a>). Paclitaxel carries a higher rate of neurotoxicity (peripheral neuropathy), whereas docetaxel has been associated with a higher rate of neutropenia (low white blood cell count) (<a href="./references#CD008766-bbs2-0047" title="HsuY , SoodAK , SoroskyJI . Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. American Journal of Clinical Oncology2004;27(1):14-8.">Hsu 2004</a>; <a href="./references#CD008766-bbs2-0097" title="VaseyPA , JaysonGC , GordonA , GabraH , ColemanR , AtkinsonR , et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute2004;96(22):1682-91.">Vasey 2004</a>). Due to nonlinear pharmacokinetics, neutropenia in response to paclitaxel treatment was found not to be related to plasma peak concentrations or AUC but rather the duration of time that plasma concentrations were greater than 50 nM (<a href="./references#CD008766-bbs2-0037" title="GianniL , KearnsCM , GianiA , CapriG , ViganoL , LocatelliA , et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. Journal of Clinical Oncology1995;13(1):180-90.">Gianni 1995</a>). Therefore, shorter infusions of paclitaxel should be associated with fewer adverse clinical outcomes (<a href="./references#CD008766-bbs2-0038" title="GligorovJ , LotzJP . Preclinical pharmacology of the taxanes: implications of the differences. Oncologist2004;9(S2):3-8.">Gligorov 2004</a>). </p> <p>It is therefore important to investigate the schedule of administration of taxanes as salvage therapy. A recent study has suggested that weekly paclitaxel was superior to three‐weekly paclitaxel in terms of survival benefits, quality of life, and toxicity in platinum‐resistant epithelial ovarian cancer (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>). In the UK, three‐weekly paclitaxel is the licensed regimen, but it is established clinical practice to use weekly paclitaxel for treating platinum‐resistant disease (<a href="./references#CD008766-bbs2-0070" title="NICE. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer: Technology appraisal guidance [TA389]. www.nice.org.uk/guidance/ta389 (accessed prior to 12 June 2022).">NICE 2016</a>). </p> </section> <section id="CD008766-sec-0013"> <h3 class="title" id="CD008766-sec-0013">Why it is important to do this review</h3> <p>The most effective and tolerable regimen of taxane monotherapy in recurrent epithelial ovarian cancer has yet to be established. In addition, findings from a 2007 systematic review suggested that an improved response to paclitaxel salvage therapy might occur in women who receive paclitaxel as part of first‐line therapy compared with those who do not (<a href="./references#CD008766-bbs2-0086" title="StordalB , PavlakisN , DaveyR . A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treatment Reviews2007;33(8):688-703.">Stordal 2007a</a>); however, this finding remains uncertain. An up‐to‐date systematic review of the literature is therefore needed to guide the use of taxanes for recurrent epithelial ovarian cancer. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008766-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008766-sec-0014"></div> <p>To assess the efficacy and toxicity of different taxane monotherapy regimens for women with recurrent epithelial ovarian, tubal or primary peritoneal cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008766-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008766-sec-0015"></div> <section id="CD008766-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008766-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs).</p> </section> <section id="CD008766-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adult women (aged 18 and over) diagnosed with epithelial ovarian, tubal or primary peritoneal cancer (FIGO stage I to IV), previously treated with platinum‐based chemotherapy, and with recurrent disease. </p> </section> <section id="CD008766-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing two or more taxane monotherapy regimens. We compared weekly versus three‐weekly administration. We also compared different doses of taxane when administered three‐weekly (135 mg/m<sup>2</sup>, 175 mg/m<sup>2</sup>, and 250 mg/m<sup>2</sup>). </p> <p>We excluded trials comparing taxane monotherapy to combination chemotherapy or targeted therapies; trials using other chemical derivatives of taxanes, such as taxanes bound to proteins or nanoparticles; and trials of maintenance chemotherapy for women following front‐line cancer treatment with no evidence of recurrence. </p> </section> <section id="CD008766-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD008766-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008766-list-0001"> <li> <p>Overall survival (OS): survival until death from all causes. We assessed survival from the time when women were enrolled in the study. </p> </li> <li> <p>Response rate: the sum of complete and partial responders as defined by a standardised response criterion such as <b>R</b> esponse <b>E</b> valuation <b>C</b> riteria <b>I</b> n <b>S</b> olid <b>T</b>umours (RECIST) or that of the World Health Organization (WHO) (<a href="./references#CD008766-bbs2-0061" title="LitièreS , ColletteS , De VriesEG , SeymourL , BogaertsJ . RECIST - learning from the past to build the future. Nature Reviews. Clinical Oncology2017;14(3):187-92.">Litière 2016</a>; <a href="./references#CD008766-bbs2-0076" title="ParkJO , LeeSI , SongSY , KimK , KimWS , JungCW , et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Japanese Journal of Clinical Oncology2003;33(10):533-7.">Park 2003</a>). </p> </li> <li> <p>Quality of life, measured using a scale that has been validated through reporting of norms in a peer‐reviewed publication (<a href="./references#CD008766-bbs2-0024" title="CellaDF , TulskyDS , GrayG , SarafianB , LinnE , BonomiA , et al. The functional assessment of cancer therapy scale: development and validation of the general measure. Journal of Clinical Oncology 1993;11(3):570-9.">Cella 1993</a>; <a href="./references#CD008766-bbs2-0085" title="SpitzerWO , DobsonAJ , HallJ , ChestermanE , LeviJ , ShepherdR , et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. Journal of Chronic Diseases1981;34(12):585-97.">Spitzer 1981</a>). </p> </li> </ul> </p> </section> <section id="CD008766-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008766-list-0002"> <li> <p>Progression‐free survival (PFS): survival until progression of disease. We assessed survival from the time when women were enrolled in the study. </p> </li> <li> <p>Neurotoxicity (Grade 3 to 4) as defined by the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE) (<a href="./references#CD008766-bbs2-0094" title="TrottiA , ColevasAD , SetserA , RuschV , JaquesD , BudachV , et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology2003;13(3):176-81.">Trotti 2003</a>). </p> </li> <li> <p>Neutropenia (Grade 3 to 4) as defined by the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE) (<a href="./references#CD008766-bbs2-0094" title="TrottiA , ColevasAD , SetserA , RuschV , JaquesD , BudachV , et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology2003;13(3):176-81.">Trotti 2003</a>). </p> </li> <li> <p>Alopecia (Grade 3 to 4) as defined by the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE) (<a href="./references#CD008766-bbs2-0094" title="TrottiA , ColevasAD , SetserA , RuschV , JaquesD , BudachV , et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology2003;13(3):176-81.">Trotti 2003</a>). </p> </li> </ul> </p> <p>We have presented Summary of findings tables reporting the following outcomes listed in order of priority: </p> <p> <ul id="CD008766-list-0003"> <li> <p>OS</p> </li> <li> <p>Response rate</p> </li> <li> <p>Quality of life</p> </li> <li> <p>PFS</p> </li> <li> <p>Neurotoxicity (Grade 3 to 4)</p> </li> <li> <p>Neutropenia (Grade 3 to 4)</p> </li> <li> <p>Alopecia (Grade 3 to 4)</p> </li> </ul> </p> </section> </section> </section> <section id="CD008766-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>There were no language or date restrictions for our searches. However, no studies that were published in a language other than English were identified in our search so translation services were not required. </p> <section id="CD008766-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases up to the 22nd of March 2022:</p> <p> <ul id="CD008766-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2022, Issue 3), in the Cochrane Library; </p> </li> <li> <p>MEDLINE via Ovid (1946 to 21 March 2022);</p> </li> <li> <p>Embase via Ovid (1980 to 2022, week 11);</p> </li> <li> <p>PubMed (1996 to 22 March 2022).</p> </li> </ul> </p> <p>The Cochrane CENTRAL search strategy is presented in <a href="./appendices#CD008766-sec-0117">Appendix 1</a>, the MEDLINE/Pubmed search strategy in <a href="./appendices#CD008766-sec-0118">Appendix 2</a>, and the Embase search strategy is in <a href="./appendices#CD008766-sec-0119">Appendix 3</a>. </p> </section> <section id="CD008766-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We identified all relevant articles on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank">ncbi.nlm.nih.gov/pubmed</a>) and made a further search for newly published articles using the 'related articles' feature<i>.</i> </p> <section id="CD008766-sec-0026"> <h5 class="title">Unpublished and grey literature</h5> <p>We searched the following for ongoing trials.</p> <p> <ul id="CD008766-list-0005"> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com/page/mrct" target="_blank">www.isrctn.com/page/mrct</a>); </p> </li> <li> <p>Physicians Data Query (<a href="http://www.cancer.gov/publications/pdq" target="_blank">www.cancer.gov/publications/pdq</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>). </p> </li> </ul> </p> </section> <section id="CD008766-sec-0027"> <h5 class="title">Handsearching</h5> <p>We handsearched the citation lists of included studies. We also handsearched the reports of conferences from the following sources. The date range of our searches was 1983 to the present as the first clinical trials of paclitaxel started in 1983 (<a href="./references#CD008766-bbs2-0029" title="DonehowerRC . The clinical development of paclitaxel: a successful collaboration of academia, industry and the National Cancer Institute. Oncologist1996;1(4):240-3.">Donehower 1996</a>). </p> <p> <ul id="CD008766-list-0006"> <li> <p><i>Gynecologic Oncology</i> (Annual Meeting of the American Society of Gynecologic Oncology); </p> </li> <li> <p><i>International Journal of Gynecological Cancer</i> (Annual Meeting of the International Gynecologic Cancer Society); </p> </li> <li> <p><i>British Journal of Cancer</i>; </p> </li> <li> <p>British Cancer Research Meeting;</p> </li> <li> <p>Annual Meeting of European Society of Medical Oncology (ESMO);</p> </li> <li> <p>Annual Meeting of the American Society of Clinical Oncology (ASCO).</p> </li> </ul> </p> </section> </section> </section> <section id="CD008766-sec-0028"> <h3 class="title" id="CD008766-sec-0028">Data collection and analysis</h3> <section id="CD008766-sec-0029"> <h4 class="title">Selection of studies</h4> <p>We uploaded all the titles and abstracts retrieved by electronic searching to <a href="./references#CD008766-bbs2-0027" title="Covidence Systematic Review Software. Melbourne, Australia: Veritas Health Innovation, 2020.">Covidence Systematic Review Software</a> which removes duplicates. Two review authors (AP, BS) examined the remaining references independently. We excluded those studies that clearly did not meet the inclusion criteria, and obtained copies of the full text of potentially relevant references. Independently, two review authors (AP, BS) assessed the eligibility of the retrieved reports/publications. Any disagreements were resolved by a third author (NH). We identified and excluded duplicate reports and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and a <a href="./references#CD008766-sec-0130" title="">Characteristics of excluded studies</a> table (<a href="./references#CD008766-bbs2-0060" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine2009;6:e1000100.">Liberati 2009</a>). </p> </section> <section id="CD008766-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Independently, two review authors (AP, BS) extracted the study characteristics and outcome data from included studies using Covidence. We noted in the <a href="./references#CD008766-sec-0129" title="">Characteristics of included studies</a> table if outcome data were not reported in a usable way. We resolved disagreements by a third person reviewing (NH). The data were downloaded from Covidence into the Review Manager 5 (RevMan 5) software (<a href="./references#CD008766-bbs2-0082" title="Review Manager 5 (RevMan 5). Version 5.4.1. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2022.">Review Manager 2022</a>)<i>.</i> We double‐checked that data had been transferred correctly by comparing the data presented in the systematic review with the study reports. One author (NH) 'spot‐checked' the accuracy of the study characteristics against the trial report. </p> <p>For included studies, we extracted the following data.</p> <p> <ul id="CD008766-list-0007"> <li> <p>Author, year of publication and journal citation (including language)</p> </li> <li> <p>Participating countries</p> </li> <li> <p>Start and end date of participant enrolment</p> </li> <li> <p>Study design</p> </li> <li> <p>Study population</p> <ul id="CD008766-list-0008"> <li> <p>Total number enrolled, total number eligible and total number treated</p> </li> <li> <p>Age (median)</p> </li> <li> <p>Number of previous regimens of chemotherapy (dichotomised 1 or 2; and ≥ 3)</p> </li> <li> <p>FIGO stage FIGO stage (dichotomised I or II; and III or IV)</p> </li> <li> <p>Performance status (dichotomised 0 to 2; and ≥ 3)</p> </li> <li> <p>Histology (dichotomised serous or non‐serous)</p> </li> <li> <p>Taxane pre‐treatment status (dichotomised naive or pre‐treated; women recruited prior to 1995 were assumed to be taxane‐naive) </p> </li> <li> <p>Platinum resistance status (dichotomised platinum‐resistant or ‐sensitive; platinum‐refractory participants were included with resistant) </p> </li> </ul> </li> <li> <p>Intervention details</p> <ul id="CD008766-list-0009"> <li> <p>Taxane</p> </li> <li> <p>Treatment Interval</p> </li> <li> <p>Dose of drug</p> </li> <li> <p>Method of administration</p> </li> </ul> </li> <li> <p>Risk of bias in study (see below)</p> </li> <li> <p>Duration of follow‐up</p> </li> <li> <p>Outcomes: for each outcome, we extracted the outcome definition and unit of measurement (if relevant). For adjusted estimates, we recorded variables adjusted for analyses. </p> </li> <li> <p>Results: we extracted the number of participants allocated to each intervention group, the total number analysed for each outcome, and the missing participants. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Results were extracted as follows:</p> <p> <ul id="CD008766-list-0010"> <li> <p>For time‐to‐event data (survival and disease progression), we extracted the HR (hazard ratio) and 95% CI (confidence interval) and then converted these to a log(HR) and these were entered in RevMan 5. If the 95% CI was not reported, we estimated the log(HR) and its standard error using the methods of <a href="./references#CD008766-bbs2-0077" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a> and <a href="./references#CD008766-bbs2-0092" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(1):16.">Tierney 2007</a>. </p> </li> <li> <p>For dichotomous outcomes (e.g. adverse events or response), we extracted the number of participants in each treatment arm who experienced the outcome of interest and the number of participants assessed at endpoint, in order to estimate a risk ratio. </p> </li> <li> <p>For continuous outcomes (e.g. QoL (quality of life) measures), we did not extract these as no included study provided any numerical data on this outcome. </p> </li> </ul> </p> <p>All data extracted was on an intention‐to‐treat basis, in which we planned to analyse participants in the groups to which they were assigned. </p> </section> <section id="CD008766-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed and reported on the methodological risk of bias of included studies in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008766-bbs2-0045" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>), which recommends the explicit reporting of the following individual elements for RCTs (<a href="./appendices#CD008766-sec-0120">Appendix 4</a>). </p> <p> <ol id="CD008766-list-0011"> <li> <p>Selection bias: random sequence generation and allocation concealment</p> </li> <li> <p>Performance bias: blinding of participants and personnel (i.e. treatment providers)</p> </li> <li> <p>Detection bias: blinding of outcome assessment</p> </li> <li> <p>Attrition bias: incomplete outcome data</p> </li> <li> <p>Reporting bias: selective reporting of outcomes</p> </li> <li> <p>Other possible sources of bias, such as the source of funding for the study</p> </li> </ol> </p> <p>Two review authors (BS, AP) applied the Risk of bias tool independently and resolved differences by discussion or by appeal to a third review author (NH). We judged each item as being at high, low or unclear risk of bias as set out in the criteria provided by <a href="./references#CD008766-bbs2-0045" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>, and provided a quote from the study report or a statement (or both) as justification for the judgement for each item in the Risk of bias table. We summarised the results in both a Risk of bias graph (<a href="#CD008766-fig-0001">Figure 1</a>) and a Risk of bias summary (<a href="#CD008766-fig-0002">Figure 2</a>). When interpreting treatment effects and meta‐analyses, we took into account the risk of bias for the studies that contributed to that outcome. Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the Risk of bias table. </p> <div class="figure" id="CD008766-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD008766-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD008766-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008766-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <p>We defined the following endpoints as subjective outcomes: progression‐free survival, response, neurotoxicity, alopecia and quality of life. </p> <p>We defined the following endpoints as objective outcomes: overall survival, neutropenia.</p> </section> <section id="CD008766-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We used the following measures of the effect of treatment.</p> <p> <ul id="CD008766-list-0012"> <li> <p>For time‐to‐event data, we used the hazard ratio (HR).</p> </li> <li> <p>For dichotomous outcomes, we analysed the data based on the number of events and the number of women assessed in the intervention and comparison groups. We used these to calculate the risk ratio (RR) and 95% confidence interval (CI). </p> </li> <li> <p>No data were extracted for continuous outcomes. Included studies did not report quality of lIfe in an extractable format. </p> </li> </ul> </p> <p>We undertook meta‐analyses only where it was meaningful, i.e. if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense. </p> </section> <section id="CD008766-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>Two review authors (BS and NH) reviewed unit of analysis issues according to guidelines described in <a href="./references#CD008766-bbs2-0045" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>. Possible unit of analysis issues included studies where there were multiple observations for the same outcome; such as repeated toxicity measurements. However, this issue was not relevant for our included studies. </p> </section> <section id="CD008766-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact study authors to obtain missing data (participant, outcome, or summary data). For participant data, we conducted our analysis on an intention‐to‐treat (ITT) basis; otherwise, we analysed the data as reported. We reported on the levels of loss to follow‐up and assessed this as a source of potential bias. For missing outcome or summary data, we did not impute missing data. </p> </section> <section id="CD008766-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>The studies we identified were similar enough, based on consideration of ovarian cancer populations and interventions, to allow pooling of data using meta‐analysis. This was a qualitative approach based on the observations of what a typical ovarian cancer clinical trial population is like from previous systematic reviews conducted by the authors (<a href="./references#CD008766-bbs2-0086" title="StordalB , PavlakisN , DaveyR . A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treatment Reviews2007;33(8):688-703.">Stordal 2007a</a>; <a href="./references#CD008766-bbs2-0087" title="StordalB , PavlakisN , DaveyR . Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treatment Reviews2007;33(4):347-57.">Stordal 2007b</a>; <a href="./references#CD008766-bbs2-0088" title="StordalB , DaveyM . Understanding cisplatin resistance using cellular models. International Union of Biochemistry &amp; Molecular Biology Life2007;59(11):696-9.">Stordal 2007c</a>) The clinical markers of participant heterogeneity that we assessed for similarity across our studies were as follows: </p> <p> <ul id="CD008766-list-0013"> <li> <p>Age (median)</p> </li> <li> <p>Number of previous regimens of chemotherapy (dichotomised 1 or 2; and ≥ 3)</p> </li> <li> <p>FIGO stage (dichotomised I or II; and III or IV)</p> </li> <li> <p>Performance status (dichotomised 0 to 2 or 3+)</p> </li> <li> <p>Histology (dichotomised serous or non‐serous)</p> </li> </ul> </p> <p>Study heterogeneity was also considered when making final recommendations as part of the GRADE approach (<a href="./references#CD008766-bbs2-0041" title="GRADEpro GDT. Version (accessed 9 April 2018). Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEPro GDT</a>). An I<sup>2</sup> higher than 40% was indicative of moderate heterogeneity between studies. </p> </section> <section id="CD008766-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess funnel plot symmetry visually for meta analyses of more than 10 studies; and, if asymmetry was suggested, we planned to perform exploratory analyses to investigate it. However, we did not have enough included studies to perform this. </p> </section> <section id="CD008766-sec-0037"> <h4 class="title">Data synthesis</h4> <p>A sufficient number of clinically similar studies (in terms of participants, settings, intervention, comparison and outcome measures) were available to ensure meaningful conclusions. </p> <p> <ul id="CD008766-list-0014"> <li> <p>For time‐to‐event data, we pooled HRs using the generic inverse variance facility in <a href="./references#CD008766-bbs2-0082" title="Review Manager 5 (RevMan 5). Version 5.4.1. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2022.">Review Manager 2022</a>. </p> </li> <li> <p>For any dichotomous outcomes, we calculated the risk ratio (RR) and 95% confidence interval (CI) for each study and these were pooled using a random‐effects Mantel‐Haenszel model (<a href="./references#CD008766-bbs2-0082" title="Review Manager 5 (RevMan 5). Version 5.4.1. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2022.">Review Manager 2022</a>). </p> </li> <li> <p>No data were extracted for continuous outcomes. Included studies did not report quality of lIfe in an extractable format. </p> </li> </ul> </p> <p>We presented the major outcomes and results, organised by intervention categories such as 'weekly administration' or 'three‐weekly administration'. In some cases, we were also able to organise the data by our identified participant subgroups of 'platinum‐resistant' or 'platinum‐sensitive'. </p> </section> <section id="CD008766-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where possible, we performed subgroup analyses for platinum‐resistance status. We also considered factors such as age, FIGO stage, number of cycles of prior chemotherapy, performance status, histology, length of follow‐up, and risk of bias status in interpretation of any heterogeneity. </p> </section> <section id="CD008766-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We had intended to perform sensitivity analyses, excluding studies with a high risk of bias, to determine the impact of these studies on the final outcome of the review. However, this was not possible due to limited included studies and all included studies having a low risk of bias. </p> </section> <section id="CD008766-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We have presented the overall certainty of the evidence for each outcome according to the GRADE approach, which takes into account issues not only related to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity such as directness of results (<a href="./references#CD008766-bbs2-0058" title="LangendamMW , AklEA , DahmP , GlasziouP , GuyattG , SchunemannHJ . Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews2013;2:81.">Langendam 2013</a>; <a href="./references#CD008766-bbs2-0084" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/current/chapter-14. [www.cochrane-handbook.org]">Schünemann 2020</a>). We created a Summary of findings table based on the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD008766-bbs2-0045" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>); and using <a href="./references#CD008766-bbs2-0041" title="GRADEpro GDT. Version (accessed 9 April 2018). Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEPro GDT</a>. We used the GRADE checklist and GRADE Working Group certainty of evidence definitions (<a href="./references#CD008766-bbs2-0066" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82.">Meader 2014</a>). We downgraded the evidence from 'high certainty' by one level for each of the following limitations: </p> <p> <ul id="CD008766-list-0015"> <li> <p>Imprecision ‐ fewer than 300 events</p> </li> <li> <p>Imprecision ‐ fewer than five studies</p> </li> <li> <p>Imprecision ‐ 95% CI included both appreciable benefit and appreciable harm</p> </li> <li> <p>Inconsistency ‐ I<sup>2</sup> higher than 40% indicating moderate heterogeneity between studies </p> </li> </ul> </p> <p>The certainty definitions were as follows (<a href="./references#CD008766-bbs2-0041" title="GRADEpro GDT. Version (accessed 9 April 2018). Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEPro GDT</a>; <a href="./references#CD008766-bbs2-0066" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82.">Meader 2014</a>): </p> <p> <ul id="CD008766-list-0016"> <li> <p><b>High‐certainty</b>: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p><b>Moderate‐certainty</b>: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p><b>Low‐certainty</b>: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p><b>Very low‐certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect. </p> </li> </ul> </p> <p>The review's main outcomes in order of priority were:</p> <p> <ul id="CD008766-list-0017"> <li> <p>overall survival (OS);</p> </li> <li> <p>response rate;</p> </li> <li> <p>progression‐free survival (PFS);</p> </li> <li> <p>neutropenia (Grade 3 to 4);</p> </li> <li> <p>neurotoxicity (Grade 3 to 4);</p> </li> <li> <p>alopecia (Grade 3 to 4);</p> </li> <li> <p>quality of life.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008766-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008766-sec-0041"></div> <section id="CD008766-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD008766-sec-0043"> <h4 class="title">Results of the search</h4> <p>Our literature search yielded 1500 references which were imported into <a href="./references#CD008766-bbs2-0027" title="Covidence Systematic Review Software. Melbourne, Australia: Veritas Health Innovation, 2020.">Covidence Systematic Review Software</a> as 1374 studies removing duplicates; no additional studies were identified by searching grey literature or handsearching (<a href="#CD008766-fig-0003">Figure 3</a>). We screened 1374 studies at the title and abstract stage. Of these, 19 studies were identified for full‐text screening. We ultimately included four studies in the qualitative analysis and two studies in the quantitative analysis. The reasons for exclusion at the full‐text screening stage are summarised in the study flow diagram (<a href="#CD008766-fig-0003">Figure 3</a>), with further details provided in the ‘<a href="./references#CD008766-sec-0130" title="">Characteristics of excluded studies</a>’ table. </p> <div class="figure" id="CD008766-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="original image" data-id="CD008766-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD008766-sec-0044"> <h4 class="title">Included studies</h4> <p>The details of the included studies are presented in the '<a href="./references#CD008766-sec-0129" title="">Characteristics of included studies</a>’ table. </p> <section id="CD008766-sec-0045"> <h5 class="title">Source of data</h5> <p>All included trials were identified through the literature search (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>; <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). </p> </section> <section id="CD008766-sec-0046"> <h5 class="title">Study design and settings</h5> <p>All included studies were parallel‐group RCTs (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>; <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). All trials were multicentred, and conducted in a hospital setting. The included studies were performed in Canada/Europe (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>), the USA (<a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>), Egypt (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>) and Sweden (<a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). Accrual periods ranged from 1991 to 1998 (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>) as well as a more recent study which recruited from 2010 to 2014 (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>). </p> </section> <section id="CD008766-sec-0047"> <h5 class="title">Participants</h5> <p>This review included a total of 981 randomised eligible participants with recurrent epithelial ovarian cancer. The median age of the participants was reported for each arm within each randomised study and ranged between 56 to 62 years; the overall age range of participants was 18 to 88 years. </p> <p>Participants had histologically‐confirmed epithelial ovarian cancer (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). The other study also included participants with primary peritoneal cancer (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>). The proportion of participants with serous histology was reported in three studies and varied between 56% to 85% (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>; <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>). All participants had a performance status of 0 to 2. FIGO staging was not reported in any of the studies. </p> <p>All participants had been previously treated with one to two cycles of platinum‐based chemotherapy and had recurrent disease. In studies from the 1990s, the participants were taxane‐naive and included those who were platinum‐sensitive as well as platinum‐resistant (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). In the more recent study from the 2010s, the participants were taxane pre‐treated and were platinum‐resistant (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>). In total, there were 926 taxane‐naive participants (94.4%), and 55 taxane pre‐treated participants (5.6%). There were also 696 platinum‐resistant participants (71%) and 285 platinum‐sensitive participants (29%). </p> </section> <section id="CD008766-sec-0048"> <h5 class="title">Interventions</h5> <p>All studies examined paclitaxel; there were no randomised controlled trials identified using docetaxel. All studies examined paclitaxel as a three‐weekly regimen. Two studies compared weekly versus three‐weekly paclitaxel (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). Two studies compared doses of paclitaxel within the three‐weekly regimen, 135 mg/m<sup>2</sup> versus 175 mg/m<sup>2</sup> (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>) and 175 mg/m<sup>2</sup> versus 250 mg/m<sup>2</sup> (<a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>). </p> </section> <section id="CD008766-sec-0049"> <h5 class="title">Outcomes</h5> <p>All included studies reported overall survival, response rate, progression‐free survival, neutropenia and neurotoxicity (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>; <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). Follow‐up time was 24 months for three studies (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>) and 36 months for one study (<a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>). Two studies reported alopecia (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>); two studies performed a quality‐of‐life analysis but did not present the data in a way that could be extracted (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>). </p> </section> </section> <section id="CD008766-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We excluded 15 studies at the full‐text review stage; see '<a href="./references#CD008766-sec-0130" title="">Characteristics of excluded studies</a>' table. </p> <p>Six were non‐randomised studies (<a href="./references#CD008766-bbs2-0007" title="Du BoisA , LuckHJ , BuserK , MeerpohlHG , SessaC , KlaassenU , et al. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. European Journal of Cancer1997;33(3):379-84. ">Du Bois 1997</a>; <a href="./references#CD008766-bbs2-0011" title="MarkmanM , HallJ , SpitzD , WeinerS , CarsonL , Van LeL , et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. Journal of Clinical Oncology2002;20(9):2365-9. ">Markman 2002</a>; <a href="./references#CD008766-bbs2-0013" title="MayerhoferK , KuceraE , ZeislerH , SpeiserP , ReinthallerA , SeveldaP . Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Gynecologic Oncology1997;64(1):109-13. ">Mayerhofer 1997</a>; <a href="./references#CD008766-bbs2-0014" title="NardiM , AloeA , De MarcoS , CognettiF , IacovelliA , AtlanteG , et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. American Journal of Clinical Oncology1997;20(3):230-2. ">Nardi 1997</a>; <a href="./references#CD008766-bbs2-0017" title="TinkerAV , GebskiV , FitzharrisB , BuckM , Stuart-HarrisR , BealeP , et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01. Gynecologic Oncology2007;104(3):647-53. ">Tinker 2007</a>; <a href="./references#CD008766-bbs2-0019" title="TropeC , HogbergT , KaernJ , BertelsenK , BjorkholmE , BomanK , et al. Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Annals of Oncology1998;9(12):1301-7. ">Trope 1998</a>), four were maintenance chemotherapy and not the treatment of relapsed patients (<a href="./references#CD008766-bbs2-0006" title="ContePF , FavalliG , GadducciA , KatsarosD , Benedetti PaniciPL , CarpiA , et al. Final results of After-6 protocol 1: a phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT). Journal of Clinical Oncology2007;25(18 Suppl):5505. ">Conte 2007</a>; <a href="./references#CD008766-bbs2-0008" title="FavalliG , ContePF , KatzarosD , ZolaP , NanniO , Gadducci Angiolo, et al. Randomized phase III trial of observation versus 6 courses of single agent paclitaxel in patients with advanced ovarian cancer who attained a complete response to platinum-paclitaxel based chemotherapy. An Italian study (AFTER-6 protocol 1). Journal of Clinical Oncology2002;27(28):4642-8. ">Favalli 2002</a>; <a href="./references#CD008766-bbs2-0012" title="MarkmanM , LiuPY , WilczynskiS , MonkB , CopelandLJ , AlvarezRD , et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. Journal of Clinical Oncology2003;21(13):2460-5. ">Markman 2003</a>; <a href="./references#CD008766-bbs2-0015" title="PecorelliS , FavalliG , GadducciA , KatsarosD , PaniciPB , CarpiA , et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol. Journal of Clinical Oncology2009;27(28):4642-6. ">Pecorelli 2009</a>). Three had a wrong non‐taxane comparator (<a href="./references#CD008766-bbs2-0005" title="CantuMG , BudaA , ParmaG , RossiR , FlorianiI , BonazziC ,  et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. Journal of Clinical Oncology2002;20(5):1232-7. ">Cantu 2002</a>; <a href="./references#CD008766-bbs2-0016" title="PiccartMJ , GreenJA , LacaveAJ , ReedN , VergoteI , Benedetti-PaniciP , et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology group. Journal of Clinical Oncology2000;18(6):1193-202. ">Piccart 2000</a>; <a href="./references#CD008766-bbs2-0018" title="TorriV ,  FlorianiI , TinazziA , ContePF , RavaioliA , CantuMG , et al. Randomized trial comparing paclitaxel + doxorubicin (AT) versus paclitaxel (T) as second line therapy for advanced ovarian cancer (AOC) patients in early progression after platinum based chemotherapy. American Society of Clinical Oncology (proceedings)2000;19:381a, Abstract 1506. ">Torri 2000</a>),  and one was the wrong intervention (<a href="./references#CD008766-bbs2-0010" title="LedermannJA . Randomized trial of paclitaxel in combination with platinum chemotherapy versus platinum/based chemotherapy in the treatment of relapsed ovarian cancer (ICON4/OVAR 2.2). American Society of Clinical Oncology2003:446 Abstract no. 1794. ">Ledermann 2003</a>). One study was excluded as, although it was a randomised trial studying paclitaxel in ovarian cancer, it was a pharmacokinetic study and contained no survival, response or relevant toxicity data required for this review (<a href="./references#CD008766-bbs2-0009" title="HuizingMT , KeungAC , RosingH , Van der KuijV , Ten Bokkel HuininkWW , MandjesIM , et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. Journal of Clinical Oncology1993;11:2127-35. [DOI: 10.1200/jco.1993.11.11.2127]">Huizing 1993</a>). </p> </section> </section> <section id="CD008766-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>The detailed results of the risk of bias assessment are provided in <a href="#CD008766-fig-0001">Figure 1</a> and <a href="#CD008766-fig-0002">Figure 2</a>, and the judgements regarding the individual domains are provided in the <a href="./references#CD008766-sec-0129" title="">Characteristics of included studies</a> table. Overall, we believe that there was a low risk of bias in the included studies. </p> <section id="CD008766-sec-0052"> <h4 class="title">Allocation</h4> <section id="CD008766-sec-0053"> <h5 class="title">Random sequence generation</h5> <p>Two studies were categorised as being at low risk as they provided details of their randomisation procedures (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>). Two studies were categorised as having unclear risk as no information on randomisation was provided in the study (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). </p> </section> <section id="CD008766-sec-0054"> <h5 class="title">Allocation concealment</h5> <p>All four studies were categorised as having unclear risk for allocation concealment as the studies did not explicitly state that the allocation was concealed (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>; <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). </p> </section> </section> <section id="CD008766-sec-0055"> <h4 class="title">Blinding</h4> <p>All four studies were categorised as having unclear risk for blinding. None of the studies explicitly stated that participants or personnel were blinded. Two of the studies were weekly versus three‐weekly regimens and, therefore, blinding of participants and personnel was not possible (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). </p> <p>One study was categorised as having low risk for detection bias as the authors explicitly stated that radiological assessment was reviewed by an external panel of independent assessors (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>). The remaining three studies were categorised as being at unclear risk for not addressing this issue (<a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>; <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). </p> </section> <section id="CD008766-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies were categorised as having low risk of bias for incomplete outcome data as all discrepancies between participant numbers across different outcomes were explained (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). One study reported quality of life for 80% of their participants and was categorised as having unclear risk (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>). </p> </section> <section id="CD008766-sec-0057"> <h4 class="title">Selective reporting</h4> <p>QoL was inadequately reported in all included studies. One study provided QoL data for both arms of the trial together preventing a comparison between groups (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>). Another study reported that a QoL assessment had been performed, commenting that there was no difference between arms but not providing data in a readily extractable format for review (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>). <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a> reported that QoL was not recorded in a protocolised manner and <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a> did not mention QoL at all. We searched for protocols for the <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a> and <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a> studies in clinical trial databases but could not locate them; as a result, these two studies have been categorised as having an unclear risk for reporting bias. </p> </section> <section id="CD008766-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>All studies were categorised as being at low risk from other sources of bias. All studies had similar participant characteristics and a balanced distribution of baseline characteristics between groups (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>; <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). </p> </section> </section> <section id="CD008766-sec-0059"> <h3 class="title" id="CD008766-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD008766-tbl-0001"><b>Summary of findings 1</b> Weekly paclitaxel compared to three‐weekly paclitaxel for the treatment of recurrent epithelial ovarian cancer</a>; <a href="./full#CD008766-tbl-0002"><b>Summary of findings 2</b> 175 mg/m<sup>2</sup> paclitaxel compared to 250 mg/m<sup>2</sup> paclitaxel for the treatment of recurrent epithelial ovarian cancer</a>; <a href="./full#CD008766-tbl-0003"><b>Summary of findings 3</b> 135 mg/m<sup>2</sup> paclitaxel compared to 175 mg/m<sup>2</sup> paclitaxel for the treatment of recurrent epithelial ovarian cancer</a> </p> <section id="CD008766-sec-0060"> <h4 class="title">1) Weekly versus three‐weekly paclitaxel</h4> <p>Two RCTs were identified comparing weekly versus three‐weekly paclitaxel allowing us to perform a meta‐analysis on the majority of the outcomes (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). Where only one study has reported a specific outcome, we have included a summary of the results of the single study. The studies compared similar but not identical doses of paclitaxel; <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a> compared 80 mg/m<sup>2</sup> weekly paclitaxel to 175 mg/m<sup>2</sup> three‐weekly paclitaxel whereas <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a> compared 67 mg/m<sup>2</sup> weekly paclitaxel to 200 mg/m<sup>2</sup> three‐weekly paclitaxel. </p> <section id="CD008766-sec-0061"> <h5 class="title">Primary outcomes</h5> <section id="CD008766-sec-0062"> <h6 class="title">1.1) Overall survival</h6> <p>Overall survival was reported in both studies (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>) and was extracted according to the methods of <a href="./references#CD008766-bbs2-0092" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(1):16.">Tierney 2007</a>. In total, survival data were available for 135 participants treated with weekly paclitaxel and 128 participants treated with three‐weekly paclitaxel. A random‐effects model with inverse‐variance HR analysis determined that there was little or no difference between the groups but the evidence is very uncertain (HR 0.94, 95% CI 0.66 to 1.33, 2 studies, I<sup>2</sup> = 30%, 263 participants, very low‐certainty evidence) (<a href="./references#CD008766-fig-0010" title="">Analysis 1.1</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="#CD008766-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD008766-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Weekly Paclitaxel versus Three‐Weekly Paclitaxel, outcome: 1.1 Overall Survival." data-id="CD008766-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Weekly Paclitaxel versus Three‐Weekly Paclitaxel, outcome: 1.1 Overall Survival. </p> </div> </div> </div> </section> <section id="CD008766-sec-0063"> <h6 class="title">1.2) Response rate</h6> <p>Response rate was reported in both studies (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). In total, response data were available for 135 participants treated with weekly paclitaxel and 45 experienced a complete or partial response; 128 participants were treated with three‐weekly paclitaxel and 42 experienced a complete or partial response. A random‐effects Mantel‐Haenszel risk ratio analysis determined that there was little or no difference between the groups but the evidence is very uncertain (RR 1.07, 95% CI 0.78 to 1.48, 2 studies, I<sup>2</sup> = 0%, 263 participants, very low‐certainty evidence) (<a href="./references#CD008766-fig-0011" title="">Analysis 1.2</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="#CD008766-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD008766-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.2 Response rate" data-id="CD008766-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.2 Response rate </p> </div> </div> </div> <section id="CD008766-sec-0064"> <p><b>1.2.1) Subgroup analysis: Platinum‐sensitive versus platinum‐resistant disease</b></p> <p>The <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a> study had platinum‐resistant participants only, whereas the <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a> study had both platinum‐sensitive and platinum‐resistant participants. In total, response data were available for 100 platinum‐sensitive participants and 51 experienced a complete or partial response (51%); 163 participants were platinum‐resistant and 36 experienced a complete or partial response (22%). This higher response rate to taxanes in the platinum‐sensitive cohort was significant (P &lt; 0.0001 (Fisher's exact test)). </p> <p>A random‐effects Mantel‐Haenszel risk ratio analysis determined that there was little or no difference in the response of the platinum‐sensitive participants between the weekly and three‐weekly paclitaxel treatment but the evidence is very uncertain (RR 1.13, 95% CI 0.77 to 1.65, 1 study, 100 participants, very low‐certainty evidence) (<a href="./references#CD008766-fig-0011" title="">Analysis 1.2</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="#CD008766-fig-0005">Figure 5</a>). Similarly, there was little or no difference in the response of the platinum‐resistant participants between the weekly and three‐weekly paclitaxel treatment but the evidence is very uncertain (RR 0.98, 95% CI 0.55 to 1.75, 2 studies, I<sup>2</sup> = 31%, 163 participants, very low‐certainty evidence) (<a href="./references#CD008766-fig-0011" title="">Analysis 1.2</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="#CD008766-fig-0005">Figure 5</a>). The Chi<sup>2</sup> test for the difference between subgroups was also non‐significant (P = 0.69) (<a href="#CD008766-fig-0005">Figure 5</a>). </p> </section> </section> <section id="CD008766-sec-0065"> <h6 class="title">1.3) Quality of life</h6> <p>Quality of life was reported in one of the studies (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>). Quality‐of‐life data were presented for 44 out of 55 participants at baseline and 35 out of 55 participants after treatment. However, quality‐of‐life data were not divided up into the two treatment arms of the study to allow an assessment between the taxane regimens. </p> </section> </section> <section id="CD008766-sec-0066"> <h5 class="title">Secondary outcomes</h5> <section id="CD008766-sec-0067"> <h6 class="title">1.4) Progression‐free survival</h6> <p>Progression‐free survival was reported in both of the studies (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>) and extracted according to the methods of <a href="./references#CD008766-bbs2-0092" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(1):16.">Tierney 2007</a>. In total, survival data were available for 123 participants treated with weekly paclitaxel and 128 participants treated with three‐weekly paclitaxel. A random‐effects inverse‐variance HR analysis determined that there was little or no difference between the groups but the evidence is very uncertain (HR 0.83, 95% CI 0.46 to 1.52, 2 studies, I<sup>2</sup> = 79%, 263 participants, very low‐certainty evidence) (<a href="./references#CD008766-fig-0012" title="">Analysis 1.3</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="#CD008766-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD008766-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.3 Progression‐free survival" data-id="CD008766-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.3 Progression‐free survival </p> </div> </div> </div> </section> <section id="CD008766-sec-0068"> <h6 class="title">1.5) Neurotoxicity</h6> <p>Neurotoxicity was reported in both of the studies (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). In total, data were available for 134 participants treated with weekly paclitaxel and 15 experienced grade 3/4 neurotoxicity; 126 participants were treated with three‐weekly paclitaxel and 32 experienced grade 3/4 neurotoxicity. A random‐effects Mantel‐Haenszel risk ratio analysis determined that there was little or no difference between the groups but the evidence is very uncertain (RR 0.53, 95% CI 0.19 to 1.48, 2 studies, I<sup>2</sup> = 49%, 260 participants, very low‐certainty evidence) (<a href="./references#CD008766-fig-0013" title="">Analysis 1.4</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="#CD008766-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD008766-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.4 Neurotoxicity." data-id="CD008766-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.4 Neurotoxicity. </p> </div> </div> </div> </section> <section id="CD008766-sec-0069"> <h6 class="title">1.6) Neutropenia</h6> <p>Neutropenia was reported in both of the studies (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). In total, data were available for 134 participants treated with weekly paclitaxel and 25 experienced grade 3/4 neutropenia; 126 participants were treated with three‐weekly paclitaxel and 51 experienced grade 3/4 neutropenia. A random‐effects Mantel‐Haenszel risk ratio analysis determined that weekly paclitaxel may result in a reduction in neutropenia (RR 0.51, 95% CI 0.27 to 0.95, I<sup>2</sup> = 37%, 2 studies, 260 participants, low‐certainty evidence) (<a href="./references#CD008766-fig-0014" title="">Analysis 1.5</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="#CD008766-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD008766-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.5 Neutropenia" data-id="CD008766-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.5 Neutropenia </p> </div> </div> </div> </section> <section id="CD008766-sec-0070"> <h6 class="title">1.7) Alopecia</h6> <p>Alopecia was reported in one of the studies (<a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). In total, data were available for 104 participants treated with weekly paclitaxel and 48 experienced grade 3/4 alopecia; 101 participants were treated with three‐weekly paclitaxel and 80 experienced grade 3/4 alopecia. A random‐effects Mantel‐Haenszel risk ratio analysis determined that weekly paclitaxel may result in a reduction in alopecia (RR 0.58, 95% CI 0.46 to 0.73, 1 study, 205 participants, low‐certainty evidence) (<a href="./references#CD008766-fig-0015" title="">Analysis 1.6</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>). </p> </section> </section> </section> <section id="CD008766-sec-0071"> <h4 class="title">2) 175 mg/m<sup>2</sup> paclitaxel versus 250 mg/m<sup>2</sup> paclitaxel </h4> <p>One RCT was identified comparing 175 mg/m<sup>2</sup> paclitaxel versus 250 mg/m<sup>2</sup> paclitaxel administered as a three‐weekly regimen; allowing us to perform a summary for the majority of outcomes (<a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>) . </p> <section id="CD008766-sec-0072"> <h5 class="title">Primary outcomes</h5> <section id="CD008766-sec-0073"> <h6 class="title">2.1) Overall survival</h6> <p>Overall survival was reported in <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a> and extracted according to the methods of <a href="./references#CD008766-bbs2-0092" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(1):16.">Tierney 2007</a>. Survival data were available for 164 participants treated with 175 mg/m<sup>2</sup> paclitaxel and 250 participants treated with 250 mg/m<sup>2</sup> paclitaxel. A random‐effects inverse‐variance HR analysis determined that there was little to no difference between the groups (HR 0.97, 95% CI 0.75 to 1.23, 1 study, 330 participants, low‐certainty evidence) (<a href="./references#CD008766-fig-0017" title="">Analysis 2.1</a>, <a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD008766-sec-0074"> <h6 class="title">2.2) Response rate</h6> <p>Response rate was reported in <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>. Response data were available for 131 participants treated with 175 mg/m<sup>2</sup> paclitaxel and 36 experienced a complete or partial response; 134 participants were treated with 250 mg/m<sup>2</sup> paclitaxel and 49 experienced a complete or partial response. A random‐effects Mantel‐Haenszel risk ratio analysis determined that there was little to no difference between the groups but the evidence is very uncertain (RR 0.86, 95% CI 0.40 to 1.89, 1 study, 265 participants, very low‐certainty evidence) (<a href="./references#CD008766-fig-0018" title="">Analysis 2.2</a>, <a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>, <a href="#CD008766-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD008766-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 175 mg/m2 paclitaxel versus 250 mg/m2 paclitaxel, outcome: 2.2 Response rate" data-id="CD008766-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 175 mg/m<sup>2</sup> paclitaxel versus 250 mg/m<sup>2</sup> paclitaxel, outcome: 2.2 Response rate </p> </div> </div> </div> <section id="CD008766-sec-0075"> <p><b>2.2.1) Subgroup analysis: Platinum‐sensitive versus platinum‐resistant disease</b></p> <p>The <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a> study had both platinum‐sensitive and platinum‐resistant participants. Response data were available for 213 platinum‐resistant participants and 63 experienced a complete or partial response (29%); 52 participants were platinum‐sensitive and 22 experienced a complete or partial response (42%). </p> <p>A random‐effects Mantel‐Haenszel risk ratio analysis determined that 175 mg/m<sup>2</sup> paclitaxel may result in a reduction of response rate in platinum‐sensitive disease (RR 0.60, 95% CI 0.39 to 0.93, 1 study, 213 participants, low‐certainty evidence) (<a href="./references#CD008766-fig-0018" title="">Analysis 2.2</a>, <a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>, <a href="#CD008766-fig-0009">Figure 9</a>). The platinum‐sensitive participants responded better to the 250 mg/m<sup>2</sup> regimen. In contrast, there was little to no difference in the response of the platinum‐resistant participants between the different doses of paclitaxel but the evidence is very uncertain (RR 1.34, 95% CI 0.70 to 2.57, 1 study, 52 participants, very low‐certainty evidence) (<a href="./references#CD008766-fig-0018" title="">Analysis 2.2</a>, <a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>, <a href="#CD008766-fig-0009">Figure 9</a>). </p> </section> </section> <section id="CD008766-sec-0076"> <h6 class="title">2.3) Quality of life</h6> <p>Quality of life was not reported in <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>. </p> </section> </section> <section id="CD008766-sec-0077"> <h5 class="title">Secondary outcomes</h5> <section id="CD008766-sec-0078"> <h6 class="title">2.4) Progression‐free survival</h6> <p>Progression‐free survival was reported in <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a> and extracted according to the methods of <a href="./references#CD008766-bbs2-0092" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(1):16.">Tierney 2007</a>. Survival data were available for 164 participants treated with 175 mg/m<sup>2</sup> paclitaxel and 166 participants treated with 250 mg/m<sup>2</sup> paclitaxel. A random‐effects inverse‐variance HR analysis determined that there was little to no difference between the groups (HR 1.07, 95% CI 0.88 to 1.30, 1 study, 330 participants, low‐certainty evidence) (<a href="./references#CD008766-fig-0019" title="">Analysis 2.3</a>, <a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD008766-sec-0079"> <h6 class="title">2.5) Neurotoxicity</h6> <p>Neurotoxicity was reported in <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>. Data were available for 164 participants treated with 175 mg/m<sup>2</sup> paclitaxel and 11 experienced grade 3/4 neurotoxicity; 166 participants were treated with 250 mg/m<sup>2</sup> paclitaxel and 27 experienced grade 3/4 neurotoxicity. A random‐effects Mantel‐Haenszel risk ratio analysis determined that 175 mg/m<sup>2</sup> paclitaxel probably reduces neurotoxicity (RR 0.41, 95% CI 0.21 to 0.80, 1 study, 330 participants, moderate‐certainty evidence) (<a href="./references#CD008766-fig-0020" title="">Analysis 2.4</a>, <a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD008766-sec-0080"> <h6 class="title">2.6) Neutropenia</h6> <p>Neutropenia was reported in <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>. Data were available for 164 participants treated with 175 mg/m<sup>2</sup> paclitaxel and 36 experienced grade 3/4 neurotoxicity; 166 participants were treated with 250 mg/m<sup>2</sup> paclitaxel and 32 experienced grade 3/4 neutropenia. A random‐effects Mantel‐Haenszel risk ratio analysis determined that there was little to no difference in neutropenia between doses of paclitaxel (RR 1.14, 95% CI 0.74 to 1.74, 1 study, 330 participants, low‐certainty evidence) (<a href="./references#CD008766-fig-0021" title="">Analysis 2.5</a>, <a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD008766-sec-0081"> <h6 class="title">2.7) Alopecia</h6> <p>Alopecia was not reported in <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>. </p> </section> </section> </section> <section id="CD008766-sec-0082"> <h4 class="title">3) 135 mg/m<sup>2</sup> paclitaxel versus 175 mg/m<sup>2</sup> paclitaxel </h4> <p>One RCT was identified comparing 135 mg/m<sup>2</sup> paclitaxel versus 175 mg/m<sup>2</sup> paclitaxel administered as a three‐weekly regimen; allowing us to perform a summary for the majority of outcomes (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>) . </p> <section id="CD008766-sec-0083"> <h5 class="title">Primary outcomes</h5> <section id="CD008766-sec-0084"> <h6 class="title">3.1) Overall survival</h6> <p>Overall survival was reported in <a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a> and extracted according to the methods of <a href="./references#CD008766-bbs2-0092" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(1):16.">Tierney 2007</a>. Survival data were available for 199 participants treated with 135 mg/m<sup>2</sup> paclitaxel and 192 participants treated with 175 mg/m<sup>2</sup> paclitaxel. A random‐effects inverse‐variance HR analysis determined that there was little to no difference between the groups (HR 0.96, 95% CI 0.77 to 1.19, 1 study, 407 participants, low‐certainty evidence) (<a href="./references#CD008766-fig-0024" title="">Analysis 3.1</a>, <a href="./full#CD008766-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD008766-sec-0085"> <h6 class="title">3.2) Response rate</h6> <p>Response rate was reported in <a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>. Response data were available for 195 participants treated with 135 mg/m<sup>2</sup> paclitaxel and 29 experienced a complete or partial response; 187 participants were treated with 175 mg/m<sup>2</sup> paclitaxel and 37 experienced a complete or partial response. A random‐effects Mantel‐Haenszel risk ratio analysis determined that there was little to no difference between the groups (RR 0.75, 95% CI 0.48 to 1.17, 1 study, 382 participants, low‐certainty evidence) (<a href="./references#CD008766-fig-0025" title="">Analysis 3.2</a>, <a href="./full#CD008766-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD008766-sec-0086"> <h6 class="title">3.3) Quality of Life</h6> <p>Quality of life was reported in <a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a> but not in a format that could be extracted for analysis. </p> </section> </section> <section id="CD008766-sec-0087"> <h5 class="title">Secondary outcomes</h5> <section id="CD008766-sec-0088"> <h6 class="title">3.4) Progression‐free survival</h6> <p>Progression‐free survival was reported in <a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a> and extracted according to the methods of <a href="./references#CD008766-bbs2-0092" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(1):16.">Tierney 2007</a>. Survival data were available for 199 participants treated with 135 mg/m<sup>2</sup> paclitaxel and 192 participants treated with 175 mg/m<sup>2</sup> paclitaxel. A random effects inverse‐variance HR analysis determined that there was little to no difference between the groups (HR 1.09, 95% CI 0.94 to 1.28, 1 study, 407 participants, moderate‐certainty evidence) (<a href="./references#CD008766-fig-0026" title="">Analysis 3.3</a>, <a href="./full#CD008766-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD008766-sec-0089"> <h6 class="title">3.5) Neurotoxicity</h6> <p>Neurotoxicity was reported in <a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>. Data were available for 199 participants treated with 135 mg/m<sup>2</sup> paclitaxel and none experienced grade 3/4 neurotoxicity; 192 participants were treated with 175 mg/m<sup>2</sup> paclitaxel and two experienced grade 3/4 neurotoxicity. A random‐effects Mantel‐Haenszel risk ratio analysis determined that there was little to no difference between the groups (RR 0.19, 95% CI 0.01 to 3.99, 391 participants, low‐certainty evidence) (<a href="./references#CD008766-fig-0027" title="">Analysis 3.4</a>, <a href="./full#CD008766-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD008766-sec-0090"> <h6 class="title">3.6) Neutropenia</h6> <p>Neutropenia was reported in <a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>. However, data were recorded for febrile neutropenia only, not all cases of neutropenia, so we have not extracted these data. </p> </section> <section id="CD008766-sec-0091"> <h6 class="title">3.7) Alopecia</h6> <p>Alopecia was reported in <a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>. However, all participants reporting hair loss were recorded rather than those experiencing Grade 3/4 levels so we have not extracted these data. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008766-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008766-sec-0092"></div> <section id="CD008766-sec-0093"> <h3 class="title" id="CD008766-sec-0093">Summary of main results</h3> <p>This review examined randomised controlled trials of taxane monotherapy for the treatment of recurrent epithelial ovarian cancer. Four studies were identified, two examining weekly versus three‐weekly paclitaxel (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>), and two studies examining different doses of three‐weekly paclitaxel (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>). No randomised controlled trials of docetaxel were identified. </p> <p>There was little to no difference in overall survival, response rate, or progression‐free survival between any of the paclitaxel regimens when examining all participants. In contrast, 250 mg/m<sup>2</sup> paclitaxel may result in an increased response rate in platinum‐sensitive disease (<a href="./references#CD008766-fig-0018" title="">Analysis 2.2</a>, <a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>, <a href="#CD008766-fig-0009">Figure 9</a>.) Unfortunately, the <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a> study did not examine survival within its different dosage and platinum‐resistant status subgroups so it is unclear if this increased response led to increased survival. </p> <p>Differences were observed in the chemotherapy‐associated toxicities. Weekly paclitaxel may result in a reduction in neutropenia and alopecia due to the participants receiving a lower dose of the drug (<a href="./references#CD008766-fig-0014" title="">Analysis 1.5</a>, <a href="./references#CD008766-fig-0015" title="">Analysis 1.6</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="#CD008766-fig-0008">Figure 8</a>). Within the three‐weekly paclitaxel regimen, 175 mg/m<sup>2</sup> probably reduces neurotoxicity, with little to no difference in overall survival (<a href="./references#CD008766-fig-0020" title="">Analysis 2.4</a>, <a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>). </p> <p>Quality‐of‐life analysis was inadequately reported in the included studies.</p> </section> <section id="CD008766-sec-0094"> <h3 class="title" id="CD008766-sec-0094">Overall completeness and applicability of evidence</h3> <p>A limitation of this review is that the majority of participants were taxane‐naive (94.4%), with data coming from older studies (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). In contrast, it is estimated that, in the UK, 75% to 90% of women with epithelial ovarian cancer receive platinum‒paclitaxel front‐line therapy (<a href="./references#CD008766-bbs2-0069" title="NICE. Guidance on the use of paclitaxel in the treatment of ovarian cancer: Technology appraisal guidance [TA55] Published date: 22 January 2003 Last updated: 01 May 2005. www.nice.org.uk/guidance/ta55 (accessed prior to 12 June 2022).">NICE 2005</a>). Therefore, the results of this review are most applicable to the 10% to 25% of women with recurrent epithelial ovarian cancer who are taxane‐naive. </p> <p>Moreover, platinum‐based combination chemotherapy or monotherapy regimens are generally recommended over non‐platinum monotherapy for women with recurrent platinum‐sensitive epithelial ovarian cancer, who make up 50% to 65% of relapsed epithelial ovarian cancer, assuming no contraindications to platinum therapy. In most studies, taxane monotherapy was delivered after front‐line platinum‐based chemotherapy, thus as first‐line therapy for recurrent disease, except in <a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>, where two lines of chemotherapy were allowed prior to enrolment in the clinical trial. </p> <p>Therefore, this evidence is applicable to approximately 10% to 25% of women with recurrent epithelial ovarian cancer, depending on clinicians' and regional preferences with regards to the use of platinum‐based chemotherapy or not in the setting of platinum‐sensitive recurrent disease. Finally, whilst these data are informative, the number of studies were limited, and the number of participants within each study was small. For some comparisons, the power may not have been sufficient to detect an association if present. </p> <p>Another limitation of this review is that the majority of participants were under the age of 75 years which is typical of clinical trials in epithelial ovarian cancer (<a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a>; <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). Only the <a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a> study included older participants (n = 60 over the age of 70 years, with a maximum age of 88). In contrast, epithelial ovarian cancer is a disease of the elderly, incidence rates are highest in females aged 75 to 79 years (<a href="./references#CD008766-bbs2-0023" title="Cancer Research UK. Cancer incidence statistics. cancerresearchuk.org/health-professional/cancer-statistics/incidence (accessed 9 April 2021).">Cancer Research UK</a>), and elderly patients often experience greater toxicity in response to chemotherapy (<a href="./references#CD008766-bbs2-0043" title="HashiguchiY , KasaiM , FukudaT , IchimuraT , YasuiT , SumiT . Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs2015;26(10):1054-60.">Hashiguchi 2015</a>). </p> </section> <section id="CD008766-sec-0095"> <h3 class="title" id="CD008766-sec-0095">Quality of the evidence</h3> <p>There are a limited number of randomised controlled trials on this topic to provide data for this Cochrane Review. As such, when evaluating the quality of evidence using <a href="./references#CD008766-bbs2-0041" title="GRADEpro GDT. Version (accessed 9 April 2018). Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEPro GDT</a>, we have decreased the certainty in our Summary of findings tables for the following circumstances. We decreased the certainty for imprecision (where there were fewer than five studies, fewer than 300 events, or the 95% CI included both appreciable benefit and appreciable harm). We also decreased the certainty for inconsistency: I<sup>2</sup> higher than 40% indicating moderate heterogeneity between studies. Several of our forest plot analyses for the analysis of weekly versus three‐weekly paclitaxel have high I<sup>2</sup> scores (<a href="#CD008766-fig-0006">Figure 6</a>; <a href="#CD008766-fig-0007">Figure 7</a>) and the difference between the two included studies is quite apparent (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>, <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). This heterogeneity may be due to the large time span between studies or that the participants in <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a> were taxane pre‐treated. </p> </section> <section id="CD008766-sec-0096"> <h3 class="title" id="CD008766-sec-0096">Potential biases in the review process</h3> <p>Our literature search was comprehensive and conducted by two review authors (AP, BS). We searched grey literature and handsearched references of included studies. There is a possibility that we may have missed studies that were not published in English, published in non‐indexed journals, or not published at all. The number of studies included in this review was also insufficient to generate funnel plots. Therefore, we may have underestimated the risk of publication bias. </p> </section> <section id="CD008766-sec-0097"> <h3 class="title" id="CD008766-sec-0097">Agreements and disagreements with other studies or reviews</h3> <section id="CD008766-sec-0098"> <h4 class="title">Overall survival</h4> <section id="CD008766-sec-0099"> <h5 class="title">Weekly versus three‐weekly paclitaxel</h5> <p>There was little or no difference in overall survival between weekly and three‐weekly paclitaxel but the evidence is very uncertain.(<a href="./references#CD008766-fig-0010" title="">Analysis 1.1</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="#CD008766-fig-0004">Figure 4</a>). Despite the uncertainty, this finding is consistent with the wider literature of single‐arm studies examining weekly or three‐weekly paclitaxel for platinum pre‐treated epithelial ovarian cancer. In 20 studies examining three‐weekly paclitaxel from 1993 to 2002, median overall survival was 10.50 ± 3.51 months (<a href="#CD008766-tbl-0004">Table 1</a>). In five studies examining weekly paclitaxel from 2002 to 2008, median overall survival was 11.92 ± 1.63 months (<a href="#CD008766-tbl-0004">Table 1</a>). There was no significant difference between these groups (P = 0.207, <a href="#CD008766-tbl-0004">Table 1</a>). </p> <div class="table" id="CD008766-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overall and progression‐free survival: weekly or three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of 3‐weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0022" title="BruzzoneM , CatsafadosE , MigliettaL , AmorosoD , PedullaF , GiannessiPG , et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology1996;53(5):349-53.">Bruzzone 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0007" title="Du BoisA , LuckHJ , BuserK , MeerpohlHG , SessaC , KlaassenU , et al. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. European Journal of Cancer1997;33(3):379-84. ">Du Bois 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0039" title="GoreME , LevyV , RustinG , PerrenT , CalvertAH , EarlH , et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. British Journal of Cancer1995;72(4):1016-9.">Gore 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0046" title="HoekmanK , HuijskesRV , BurgerCW , VerheijenRH , PinedoHM , VermorkenJB . [Favorable results of paclitaxel (taxol) in patients with ovary carcinoma pretreated with platinum] [Dutch]. Nederlands Tijdschrift voor Geneeskunde1995;139(6):272-8.">Hoekman 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0079" title="PhillipsKA , FriedlanderM , OlverI , EvansB , SmithJ , FitzharrisB , et al. Australasian multicentre phase II study of paclitaxel (taxol) in relapsed ovarian cancer. Australian and New Zealand Journal of Medicine1995;25(4):337-43.">Phillips 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0093" title="TrimbleEL , AdamsJD , VenaD , HawkinsMJ , FriedmanMA , FishermanJS , et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. Journal of Clinical Oncology1993;11(12):2405-10.">Trimble 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0091" title="ThigpenJT , BlessingJA , BallH , HummelSJ , BarrettRJ . Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of Clinical Oncology1994;12(9):1748-53.">Thigpen 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0005" title="CantuMG , BudaA , ParmaG , RossiR , FlorianiI , BonazziC ,  et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. Journal of Clinical Oncology2002;20(5):1232-7. ">Cantu 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0032" title="EzcurdiaL , JovtisSL , MickiewiczE , TemperleyG , RondinonM , BlajmanC , et al, Argentine Multicenter Taxol group. Paclitaxel in platinum-resistant ovarian cancer patients.. Seminars in Oncology1997;24(5 Suppl 15):S15.">Ezcurdia 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0044" title="HernadiZ , HugaS , LukacskoL , KrasznaiZ , SapyT . Chemotherapy resistance of ovarian cancer patients after platinum-based therapy paclitaxel as a choice of treatment. [Hungarian]. Magyar Noorvosok Lapja2001;64(3):249-54.">Hernadi 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0048" title="IshikawaH , NakanishiT , NawaA , SuzukiY , KuzuyaK . 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. International Journal of Clinical Oncology2001;6(3):128-31.">Ishikawa 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0074" title="OliverioG , CanutiD , TononiA , ScarpelliniM , PanziniI , GalliI , et al. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients. Journal of Chemotherapy1999;11(4):301-5.">Oliverio 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0078" title="PectasidesD , PapadopoulouM , VarthalitisJ , MylonakisA , KostopoulouM , DimitriadisM , et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology1998;55(3):228-34.">Pectasides 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0016" title="PiccartMJ , GreenJA , LacaveAJ , ReedN , VergoteI , Benedetti-PaniciP , et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology group. Journal of Clinical Oncology2000;18(6):1193-202. ">Piccart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0081" title="PlannerRS , AllenDG , BrandAH , GrantPT , TonerGC , SykesPH . Paclitaxel (taxol) as salvage therapy for relapsed ovarian cancer. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(2):168-70.">Planner 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0090" title="Ten Bokkel HuininkW , GoreM , CarmichaelJ , GordonA , MalfetanoJ , HudsonI , et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology1997;15(6):2183-93.">Ten Bokkel Huinink 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0019" title="TropeC , HogbergT , KaernJ , BertelsenK , BjorkholmE , BomanK , et al. Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Annals of Oncology1998;9(12):1301-7. ">Trope 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0100" title="WilailakS , TresukosolD , LinasmitaV , TermrungruanglertW . Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer. European Journal of Gynaecological Oncology2000;21(6):610-2.">Wilailak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0055" title="KohnEC , SarosyG , BicherA , LinkC , ChristianM , SteinbergSM , et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. Journal of the National Cancer Institute1994;86(1):18-24.">Kohn 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0057" title="KudelkaA , VerschraegenC , ShenY , De LeonC , EdwardsC , FreedmanR , et al. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. International Journal of Gynaecological Cancer1999;9(1):44-53.">Kudelka 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PFS weighted mean ± SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OS weighted mean ± SD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.68 ± 1.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.50 ± 3.51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>175 mg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.85 ± 2.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.34 ± 5.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.39 ± 0.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>P value 175</b> versus <b>250 mg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.283</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0059" title="LeT , HopkinsL , BainesKA , RamboutL , Al HaykiM , Kee FungMF . Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecologic Oncology2006;102(1):49-53.">Le 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60‐80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0030" title="DunderI , BerkerB , AtabekogluC , BilginT . Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. European Journal of Gynaecological Oncology2005;26(1):79-82.">Dunder 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0052" title="KaernJ , BaekelandtM , TropéCG . A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. European Journal of Gynaecological Oncology2002;23(5):383-9.">Kaern 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0056" title="KristensenG , KaernJ , BaekelandtM , Skeie-JensensenT , De Pont ChristensenR , Avall-LundqvistE , et al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: a NSGO study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings)2008;26(Suppl):Abstract.">Kristensen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0062" title="LortholaryA , LargillierR , WeberB , GladieffL , AlexandreJ , DurandoX , et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Annals of Oncology2012;23(2):346-52.">Lortholary 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0011" title="MarkmanM , HallJ , SpitzD , WeinerS , CarsonL , Van LeL , et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. Journal of Clinical Oncology2002;20(9):2365-9. ">Markman 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0063" title="MarkmanM , BlessingJ , RubinSC , ConnorJ , HanjaniP , WaggonerS . Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecologic Oncology2006;101(3):436-40.">Markman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PFS weighted mean ± SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OS weighted mean ± SD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>All studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.38 ± 1.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.92 ± 1.63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>P value weekly</b> versus <b>3‐weekly</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.207</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ND: Not Determined<br/>NR: Not Reported<br/>SD: Standard Deviation </p> </div> </div> <p>Weekly versus three‐weekly paclitaxel has also been investigated in the front‐line treatment of epithelial ovarian cancer. A Japanese study showed a clear benefit of weekly paclitaxel compared to three‐weekly; carboplatin was also given three‐weekly in this study (<a href="./references#CD008766-bbs2-0053" title="KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6.">Katsumata 2013</a>). However, this survival benefit in a Japanese population has not been replicated in European or North American populations (<a href="./references#CD008766-bbs2-0026" title="ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95.">Clamp 2019</a>; <a href="./references#CD008766-bbs2-0025" title="ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48.">Chan 2016</a>). This is consistent to what we observed in the recurrent setting in Egyptian and Scandinavian populations (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). </p> </section> <section id="CD008766-sec-0100"> <h5 class="title">Doses of three‐weekly paclitaxel</h5> <p>There was little or no difference in overall survival between the different doses of three‐weekly paclitaxel (<a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD008766-tbl-0003">summary of findings Table 3</a>). This is consistent with the wider literature of single‐arm studies examining three‐weekly paclitaxel for platinum pre‐treated epithelial ovarian cancer. In 10 studies examining 175 mg/m<sup>2</sup> paclitaxel from 1996 to 2002, median overall survival was 13.34 ± 5.36 months (<a href="#CD008766-tbl-0004">Table 1</a>). In two studies examining 200 mg/m<sup>2</sup> paclitaxel from 1994 to 1999, median overall survival was 11.39 ± 0.14 months (<a href="#CD008766-tbl-0004">Table 1</a>). There was no significant difference between these groups (P = 0.283, <a href="#CD008766-tbl-0004">Table 1</a>). </p> </section> </section> <section id="CD008766-sec-0101"> <h4 class="title">Response rate</h4> <section id="CD008766-sec-0102"> <h5 class="title">Weekly versus three‐weekly paclitaxel</h5> <p>There was little or no difference in response rate between weekly and three‐weekly paclitaxel but the evidence is very uncertain (<a href="./references#CD008766-fig-0011" title="">Analysis 1.2</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="#CD008766-fig-0005">Figure 5</a>). This result is not consistent with the wider literature of single‐arm studies examining weekly or three‐weekly paclitaxel for platinum pre‐treated epithelial ovarian cancer. In 28 studies examining three‐weekly paclitaxel from 1994 to 2002, 651 participants experienced a complete or partial response out of a total of 2633 participants (24.7%) (<a href="#CD008766-tbl-0005">Table 2</a>). In contrast, in 12 studies examining weekly paclitaxel from 1997 to 2011, 169 participants out of a total of 471 experienced a complete or partial response (35.9%) (<a href="#CD008766-tbl-0005">Table 2</a>). This difference was significant between these groups (P = 0.0002, <a href="#CD008766-tbl-0005">Table 2</a>). It is noteworthy that the single‐arm studies in the literature agree with our review of randomised controlled trials for all outcomes except response rate. However, the increased response rate in weekly paclitaxel in the single‐arm studies did not lead to a corresponding increase in progression‐free or overall survival. </p> <div class="table" id="CD008766-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Response rate: weekly or three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3‐weekly paclitaxel study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose of 3‐weekly</b> </p> <p><b>paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete or partial response</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0064" title="McGuireWP , RowinskyEK , RosensheinNB , GrumbineFC , EttingerDS , ArmstrongDK , et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Annals of Internal.Medicine1989;111(4):273-9.">McGuire 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110‐250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0093" title="TrimbleEL , AdamsJD , VenaD , HawkinsMJ , FriedmanMA , FishermanJS , et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. Journal of Clinical Oncology1993;11(12):2405-10.">Trimble 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0022" title="BruzzoneM , CatsafadosE , MigliettaL , AmorosoD , PedullaF , GiannessiPG , et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology1996;53(5):349-53.">Bruzzone 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0007" title="Du BoisA , LuckHJ , BuserK , MeerpohlHG , SessaC , KlaassenU , et al. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. European Journal of Cancer1997;33(3):379-84. ">Du Bois 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0039" title="GoreME , LevyV , RustinG , PerrenT , CalvertAH , EarlH , et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. British Journal of Cancer1995;72(4):1016-9.">Gore 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0046" title="HoekmanK , HuijskesRV , BurgerCW , VerheijenRH , PinedoHM , VermorkenJB . [Favorable results of paclitaxel (taxol) in patients with ovary carcinoma pretreated with platinum] [Dutch]. Nederlands Tijdschrift voor Geneeskunde1995;139(6):272-8.">Hoekman 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0057" title="KudelkaA , VerschraegenC , ShenY , De LeonC , EdwardsC , FreedmanR , et al. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. International Journal of Gynaecological Cancer1999;9(1):44-53.">Kudelka 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0014" title="NardiM , AloeA , De MarcoS , CognettiF , IacovelliA , AtlanteG , et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. American Journal of Clinical Oncology1997;20(3):230-2. ">Nardi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0079" title="PhillipsKA , FriedlanderM , OlverI , EvansB , SmithJ , FitzharrisB , et al. Australasian multicentre phase II study of paclitaxel (taxol) in relapsed ovarian cancer. Australian and New Zealand Journal of Medicine1995;25(4):337-43.">Phillips 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0040" title="GoreME , PrestonN , A'HernRP , HillC , MitchellP , ChangJ , et al. Platinum-taxol non-cross resistance in epithelial ovarian cancer. British Journal of Cancer1995;71(6):1308-10.">Gore 1995a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0072" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al, BMS-181339 ovarian cancer study group. [A phase II study of BMS-181339 in patients with ovarian cancer] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1994;21(14):2461-9.">Noda 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0083" title="SarosyG , KohnE , StoneDA , RothenbergM , JacobJ , AdamoDO , et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. Journal of Clinical Oncology1992;10(7):1165-70.">Sarosy 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>170‐300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0005" title="CantuMG , BudaA , ParmaG , RossiR , FlorianiI , BonazziC ,  et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. Journal of Clinical Oncology2002;20(5):1232-7. ">Cantu 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0032" title="EzcurdiaL , JovtisSL , MickiewiczE , TemperleyG , RondinonM , BlajmanC , et al, Argentine Multicenter Taxol group. Paclitaxel in platinum-resistant ovarian cancer patients.. Seminars in Oncology1997;24(5 Suppl 15):S15.">Ezcurdia 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0044" title="HernadiZ , HugaS , LukacskoL , KrasznaiZ , SapyT . Chemotherapy resistance of ovarian cancer patients after platinum-based therapy paclitaxel as a choice of treatment. [Hungarian]. Magyar Noorvosok Lapja2001;64(3):249-54.">Hernadi 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0048" title="IshikawaH , NakanishiT , NawaA , SuzukiY , KuzuyaK . 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. International Journal of Clinical Oncology2001;6(3):128-31.">Ishikawa 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0073" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1996;23(3):317-25.">Noda 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0074" title="OliverioG , CanutiD , TononiA , ScarpelliniM , PanziniI , GalliI , et al. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients. Journal of Chemotherapy1999;11(4):301-5.">Oliverio 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0078" title="PectasidesD , PapadopoulouM , VarthalitisJ , MylonakisA , KostopoulouM , DimitriadisM , et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology1998;55(3):228-34.">Pectasides 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0016" title="PiccartMJ , GreenJA , LacaveAJ , ReedN , VergoteI , Benedetti-PaniciP , et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology group. Journal of Clinical Oncology2000;18(6):1193-202. ">Piccart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0081" title="PlannerRS , AllenDG , BrandAH , GrantPT , TonerGC , SykesPH . Paclitaxel (taxol) as salvage therapy for relapsed ovarian cancer. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(2):168-70.">Planner 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0090" title="Ten Bokkel HuininkW , GoreM , CarmichaelJ , GordonA , MalfetanoJ , HudsonI , et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology1997;15(6):2183-93.">Ten Bokkel Huinink 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0091" title="ThigpenJT , BlessingJA , BallH , HummelSJ , BarrettRJ . Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of Clinical Oncology1994;12(9):1748-53.">Thigpen 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0019" title="TropeC , HogbergT , KaernJ , BertelsenK , BjorkholmE , BomanK , et al. Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Annals of Oncology1998;9(12):1301-7. ">Trope 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0100" title="WilailakS , TresukosolD , LinasmitaV , TermrungruanglertW . Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer. European Journal of Gynaecological Oncology2000;21(6):610-2.">Wilailak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0055" title="KohnEC , SarosyG , BicherA , LinkC , ChristianM , SteinbergSM , et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. Journal of the National Cancer Institute1994;86(1):18-24.">Kohn 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2633</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>651 (24.7</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weekly paclitaxel study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete or partial response</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0033" title="FennellyD , AghajanianC , ShapiroF , O'FlahertyC , McKenzieM , O'ConnorC , et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. Journal of Clinical Oncology1997;15(1):187-92.">Fennelly 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40‐100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0059" title="LeT , HopkinsL , BainesKA , RamboutL , Al HaykiM , Kee FungMF . Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecologic Oncology2006;102(1):49-53.">Le 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60‐80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0021" title="AnderssonH , HorvathG , MellqvistL , WestbergR . Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot study. International Journal of Gynecological Cancer1997;7(4):262-6.">Andersson 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67‐81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0089" title="TakanoM , KikuchiY , KitaT , SuzukiM , OhwadaM , YamamotoT , et al. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer. Anticancer Research2002;22(3):1833-8.">Takano 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70‐100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0030" title="DunderI , BerkerB , AtabekogluC , BilginT . Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. European Journal of Gynaecological Oncology2005;26(1):79-82.">Dunder 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0036" title="GhamandeS , LeleS , MarchettiD , BakerT , OdunsiK . Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. International Journal of Gynecological Cancer2003;13(2):142-7.">Ghamande 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0052" title="KaernJ , BaekelandtM , TropéCG . A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. European Journal of Gynaecological Oncology2002;23(5):383-9.">Kaern 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0054" title="KitaT , KikuchiY , TakanoM , SuzukiM , OowadaM , KonnoR , et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecologic Oncology2004;92(3):813-8.">Kita 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0056" title="KristensenG , KaernJ , BaekelandtM , Skeie-JensensenT , De Pont ChristensenR , Avall-LundqvistE , et al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: a NSGO study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings)2008;26(Suppl):Abstract.">Kristensen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0062" title="LortholaryA , LargillierR , WeberB , GladieffL , AlexandreJ , DurandoX , et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Annals of Oncology2012;23(2):346-52.">Lortholary 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0011" title="MarkmanM , HallJ , SpitzD , WeinerS , CarsonL , Van LeL , et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. Journal of Clinical Oncology2002;20(9):2365-9. ">Markman 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0063" title="MarkmanM , BlessingJ , RubinSC , ConnorJ , HanjaniP , WaggonerS . Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecologic Oncology2006;101(3):436-40.">Markman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>471</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>169 (35.9</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Fishers Exact Test:</b> P = 0.0002 </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD008766-sec-0103"> <h4 class="title">Progression‐free survival</h4> <section id="CD008766-sec-0104"> <h5 class="title">Weekly versus three‐weekly paclitaxel</h5> <p>There was little or no difference in PFS between weekly and three‐weekly paclitaxel but the evidence is very uncertain (<a href="./references#CD008766-fig-0012" title="">Analysis 1.3</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="#CD008766-fig-0006">Figure 6</a>). This is consistent with the wider literature of single‐arm studies examining weekly or three‐weekly paclitaxel for platinum pre‐treated epithelial ovarian cancer. In 15 studies examining three‐weekly paclitaxel from 1993 to 2002, median progression‐free survival was 4.87 ± 1.69 months (<a href="#CD008766-tbl-0004">Table 1</a>). In six studies examining weekly paclitaxel from 2002 to 2011, median overall survival range was 4.37 ± 1.12 months (<a href="#CD008766-tbl-0004">Table 1</a>). There was no significant difference between these groups (P = 0.624, <a href="#CD008766-tbl-0005">Table 2</a>). </p> </section> </section> <section id="CD008766-sec-0105"> <h4 class="title">Neutropenia</h4> <section id="CD008766-sec-0106"> <h5 class="title">Weekly versus three‐weekly paclitaxel</h5> <p>The normal lower limit for neutrophils is 1.5 × 10<sup>9</sup>/L (<a href="./references#CD008766-bbs2-0068" title="TerritoM . Neutropenia - Hematology and Oncology. MSD Manual Professional Version. Available from www.msdmanuals.com/en-gb/professional/hematology-and-oncology/leukopenias/neutropenia 2021 (accessed prior to 12 June 2022).">MSD Manual 2021</a>). In cases of severe neutropenia when neutrophils drop to &lt; 0.5 × 10<sup>9</sup>/L endogenous flora in the mouth and gut can cause harmful infections, particularly in cancer patients. The included studies required participants to have a normal neutrophil count at the start of the study (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). </p> <p>Weekly paclitaxel may result in a reduction in neutropenia (<a href="./references#CD008766-fig-0014" title="">Analysis 1.5</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="#CD008766-fig-0008">Figure 8</a>). This is consistent with the wider literature of single‐arm studies examining weekly or three‐weekly paclitaxel for platinum pre‐treated epithelial ovarian cancer. In 18 studies examining three‐weekly paclitaxel from 1994 to 2002, 544 participants experienced grade 3 or 4 neutropenia out of a total of 1052 participants (51.7%) (<a href="#CD008766-tbl-0006">Table 3</a>). In contrast, in 10 studies examining weekly paclitaxel from 1997 to 2015 only 35 participants out of a total of 402 experienced grade 3 or 4 neutropenia (8.7%) (<a href="#CD008766-tbl-0006">Table 3</a>).There was a significant difference between these groups (P &lt; 0.0001,<a href="#CD008766-tbl-0006">Table 3</a>). </p> <div class="table" id="CD008766-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Neutropenia: weekly or three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of 3‐weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3 or 4 neutropenia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0022" title="BruzzoneM , CatsafadosE , MigliettaL , AmorosoD , PedullaF , GiannessiPG , et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology1996;53(5):349-53.">Bruzzone 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0039" title="GoreME , LevyV , RustinG , PerrenT , CalvertAH , EarlH , et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. British Journal of Cancer1995;72(4):1016-9.">Gore 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0046" title="HoekmanK , HuijskesRV , BurgerCW , VerheijenRH , PinedoHM , VermorkenJB . [Favorable results of paclitaxel (taxol) in patients with ovary carcinoma pretreated with platinum] [Dutch]. Nederlands Tijdschrift voor Geneeskunde1995;139(6):272-8.">Hoekman 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0014" title="NardiM , AloeA , De MarcoS , CognettiF , IacovelliA , AtlanteG , et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. American Journal of Clinical Oncology1997;20(3):230-2. ">Nardi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0079" title="PhillipsKA , FriedlanderM , OlverI , EvansB , SmithJ , FitzharrisB , et al. Australasian multicentre phase II study of paclitaxel (taxol) in relapsed ovarian cancer. Australian and New Zealand Journal of Medicine1995;25(4):337-43.">Phillips 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0072" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al, BMS-181339 ovarian cancer study group. [A phase II study of BMS-181339 in patients with ovarian cancer] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1994;21(14):2461-9.">Noda 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0091" title="ThigpenJT , BlessingJA , BallH , HummelSJ , BarrettRJ . Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of Clinical Oncology1994;12(9):1748-53.">Thigpen 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0005" title="CantuMG , BudaA , ParmaG , RossiR , FlorianiI , BonazziC ,  et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. Journal of Clinical Oncology2002;20(5):1232-7. ">Cantu 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0032" title="EzcurdiaL , JovtisSL , MickiewiczE , TemperleyG , RondinonM , BlajmanC , et al, Argentine Multicenter Taxol group. Paclitaxel in platinum-resistant ovarian cancer patients.. Seminars in Oncology1997;24(5 Suppl 15):S15.">Ezcurdia 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0048" title="IshikawaH , NakanishiT , NawaA , SuzukiY , KuzuyaK . 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. International Journal of Clinical Oncology2001;6(3):128-31.">Ishikawa 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0074" title="OliverioG , CanutiD , TononiA , ScarpelliniM , PanziniI , GalliI , et al. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients. Journal of Chemotherapy1999;11(4):301-5.">Oliverio 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0078" title="PectasidesD , PapadopoulouM , VarthalitisJ , MylonakisA , KostopoulouM , DimitriadisM , et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology1998;55(3):228-34.">Pectasides 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0016" title="PiccartMJ , GreenJA , LacaveAJ , ReedN , VergoteI , Benedetti-PaniciP , et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology group. Journal of Clinical Oncology2000;18(6):1193-202. ">Piccart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0081" title="PlannerRS , AllenDG , BrandAH , GrantPT , TonerGC , SykesPH . Paclitaxel (taxol) as salvage therapy for relapsed ovarian cancer. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(2):168-70.">Planner 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0090" title="Ten Bokkel HuininkW , GoreM , CarmichaelJ , GordonA , MalfetanoJ , HudsonI , et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology1997;15(6):2183-93.">Ten Bokkel Huinink 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0019" title="TropeC , HogbergT , KaernJ , BertelsenK , BjorkholmE , BomanK , et al. Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Annals of Oncology1998;9(12):1301-7. ">Trope 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0073" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1996;23(3):317-25.">Noda 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0057" title="KudelkaA , VerschraegenC , ShenY , De LeonC , EdwardsC , FreedmanR , et al. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. International Journal of Gynaecological Cancer1999;9(1):44-53.">Kudelka 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1052</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>544 (51.7</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3 or 4 neutropenia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0021" title="AnderssonH , HorvathG , MellqvistL , WestbergR . Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot study. International Journal of Gynecological Cancer1997;7(4):262-6.">Andersson 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67‐81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0089" title="TakanoM , KikuchiY , KitaT , SuzukiM , OhwadaM , YamamotoT , et al. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer. Anticancer Research2002;22(3):1833-8.">Takano 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70‐100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0030" title="DunderI , BerkerB , AtabekogluC , BilginT . Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. European Journal of Gynaecological Oncology2005;26(1):79-82.">Dunder 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0036" title="GhamandeS , LeleS , MarchettiD , BakerT , OdunsiK . Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. International Journal of Gynecological Cancer2003;13(2):142-7.">Ghamande 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0052" title="KaernJ , BaekelandtM , TropéCG . A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. European Journal of Gynaecological Oncology2002;23(5):383-9.">Kaern 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0054" title="KitaT , KikuchiY , TakanoM , SuzukiM , OowadaM , KonnoR , et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecologic Oncology2004;92(3):813-8.">Kita 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0062" title="LortholaryA , LargillierR , WeberB , GladieffL , AlexandreJ , DurandoX , et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Annals of Oncology2012;23(2):346-52.">Lortholary 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0011" title="MarkmanM , HallJ , SpitzD , WeinerS , CarsonL , Van LeL , et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. Journal of Clinical Oncology2002;20(9):2365-9. ">Markman 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0063" title="MarkmanM , BlessingJ , RubinSC , ConnorJ , HanjaniP , WaggonerS . Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecologic Oncology2006;101(3):436-40.">Markman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0080" title="PignataS , LorussoD , ScambiaG , SambataroD , TamberiS , CinieriS , et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncology2015;16(5):561-8.">Pignata 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>402</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>35 (8.7</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Fishers Exact Test:</b> P &lt; 0.0001 </p> </td> </tr> </tbody> </table> </div> <p>The treatment for chemotherapy‐induced neutropenia is the use of a granulocyte‐colony stimulating factor (G‐CSF) (<a href="./references#CD008766-bbs2-0043" title="HashiguchiY , KasaiM , FukudaT , IchimuraT , YasuiT , SumiT . Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs2015;26(10):1054-60.">Hashiguchi 2015</a>). However, using G‐CSF adds another cost to delivering chemotherapy. G‐CSF also has its own profile of side effects such as musculoskeletal pain and fever, and it can also induce leukaemia (<a href="./references#CD008766-bbs2-0043" title="HashiguchiY , KasaiM , FukudaT , IchimuraT , YasuiT , SumiT . Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs2015;26(10):1054-60.">Hashiguchi 2015</a>). In the included studies, dose reduction or stopping of treatment was used in the case of grade 3 or 4 neutropenia (<a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a>; <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). The <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a> study planned to give G‐CSF in the case of febrile neutropenia but it did not occur in the study. </p> <p>Increased levels of chemotherapy‐induced neutropenia has been associated with participants over 70 years of age (<a href="./references#CD008766-bbs2-0043" title="HashiguchiY , KasaiM , FukudaT , IchimuraT , YasuiT , SumiT . Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs2015;26(10):1054-60.">Hashiguchi 2015</a>). Therefore, it may be important to consider a shift to weekly paclitaxel in this cohort of patients. However, the <a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a> study did not include participants over the age of 70, and had a mean age of 56.7 years. The <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a> study, included participants up to the age of 75 years and had a median age of 59. However, there was no division of participants by age in either study so we have no evidence that the weekly‐paclitaxel regimen is superior for a cohort of older patients. </p> </section> </section> <section id="CD008766-sec-0107"> <h4 class="title">Alopecia</h4> <section id="CD008766-sec-0108"> <h5 class="title">Weekly versus three‐weekly paclitaxel</h5> <p>Weekly paclitaxel may result in a reduction in alopecia (<a href="./references#CD008766-fig-0015" title="">Analysis 1.6</a>, <a href="./full#CD008766-tbl-0001">summary of findings Table 1</a>, <a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a>). This is consistent with the wider literature of single‐arm studies examining weekly or three‐weekly paclitaxel for platinum pre‐treated epithelial ovarian cancer. In 14 studies examining three‐weekly paclitaxel from 1994 to 2001, 445 participants experienced grade 3 or 4 alopecia out of a total of 878 participants (50.1%) (<a href="#CD008766-tbl-0007">Table 4</a>). In contrast, in seven studies examining weekly paclitaxel from 1997 to 2015, only 10 participants out of a total of 267 experienced grade 3 or 4 alopecia (3.7%) (<a href="#CD008766-tbl-0007">Table 4</a>). There was a significant difference between these groups (P &lt; 0.0001, <a href="#CD008766-tbl-0007">Table 4</a>). </p> <div class="table" id="CD008766-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Alopecia: weekly or three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of 3‐weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3 or 4 alopecia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0022" title="BruzzoneM , CatsafadosE , MigliettaL , AmorosoD , PedullaF , GiannessiPG , et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology1996;53(5):349-53.">Bruzzone 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0039" title="GoreME , LevyV , RustinG , PerrenT , CalvertAH , EarlH , et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. British Journal of Cancer1995;72(4):1016-9.">Gore 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0014" title="NardiM , AloeA , De MarcoS , CognettiF , IacovelliA , AtlanteG , et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. American Journal of Clinical Oncology1997;20(3):230-2. ">Nardi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0079" title="PhillipsKA , FriedlanderM , OlverI , EvansB , SmithJ , FitzharrisB , et al. Australasian multicentre phase II study of paclitaxel (taxol) in relapsed ovarian cancer. Australian and New Zealand Journal of Medicine1995;25(4):337-43.">Phillips 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0072" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al, BMS-181339 ovarian cancer study group. [A phase II study of BMS-181339 in patients with ovarian cancer] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1994;21(14):2461-9.">Noda 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0091" title="ThigpenJT , BlessingJA , BallH , HummelSJ , BarrettRJ . Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of Clinical Oncology1994;12(9):1748-53.">Thigpen 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0032" title="EzcurdiaL , JovtisSL , MickiewiczE , TemperleyG , RondinonM , BlajmanC , et al, Argentine Multicenter Taxol group. Paclitaxel in platinum-resistant ovarian cancer patients.. Seminars in Oncology1997;24(5 Suppl 15):S15.">Ezcurdia 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0048" title="IshikawaH , NakanishiT , NawaA , SuzukiY , KuzuyaK . 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. International Journal of Clinical Oncology2001;6(3):128-31.">Ishikawa 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0078" title="PectasidesD , PapadopoulouM , VarthalitisJ , MylonakisA , KostopoulouM , DimitriadisM , et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology1998;55(3):228-34.">Pectasides 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0090" title="Ten Bokkel HuininkW , GoreM , CarmichaelJ , GordonA , MalfetanoJ , HudsonI , et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology1997;15(6):2183-93.">Ten Bokkel Huinink 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0019" title="TropeC , HogbergT , KaernJ , BertelsenK , BjorkholmE , BomanK , et al. Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Annals of Oncology1998;9(12):1301-7. ">Trope 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0100" title="WilailakS , TresukosolD , LinasmitaV , TermrungruanglertW . Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer. European Journal of Gynaecological Oncology2000;21(6):610-2.">Wilailak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0073" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1996;23(3):317-25.">Noda 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0057" title="KudelkaA , VerschraegenC , ShenY , De LeonC , EdwardsC , FreedmanR , et al. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. International Journal of Gynaecological Cancer1999;9(1):44-53.">Kudelka 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>878</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>445 (50.1</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3 or 4 alopecia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0021" title="AnderssonH , HorvathG , MellqvistL , WestbergR . Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot study. International Journal of Gynecological Cancer1997;7(4):262-6.">Andersson 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67‐81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0089" title="TakanoM , KikuchiY , KitaT , SuzukiM , OhwadaM , YamamotoT , et al. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer. Anticancer Research2002;22(3):1833-8.">Takano 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70‐100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0030" title="DunderI , BerkerB , AtabekogluC , BilginT . Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. European Journal of Gynaecological Oncology2005;26(1):79-82.">Dunder 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0052" title="KaernJ , BaekelandtM , TropéCG . A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. European Journal of Gynaecological Oncology2002;23(5):383-9.">Kaern 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0054" title="KitaT , KikuchiY , TakanoM , SuzukiM , OowadaM , KonnoR , et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecologic Oncology2004;92(3):813-8.">Kita 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0062" title="LortholaryA , LargillierR , WeberB , GladieffL , AlexandreJ , DurandoX , et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Annals of Oncology2012;23(2):346-52.">Lortholary 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0080" title="PignataS , LorussoD , ScambiaG , SambataroD , TamberiS , CinieriS , et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncology2015;16(5):561-8.">Pignata 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>267</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 (3.7</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Fishers Exact Test:</b> P &lt; 0.0001 </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD008766-sec-0109"> <h4 class="title">Neurotoxicity</h4> <section id="CD008766-sec-0110"> <h5 class="title">175 mg/m<sup>2</sup> versus 250 mg/m<sup>2</sup> paclitaxel </h5> <p>175 mg/m<sup>2</sup> paclitaxel probably reduces neurotoxicity (<a href="./references#CD008766-fig-0020" title="">Analysis 2.4</a>, <a href="./full#CD008766-tbl-0002">summary of findings Table 2</a>). This result is consistent with the wider literature of single‐arm studies examining 175 mg/m<sup>2</sup> or doses higher than 200 mg/m<sup>2</sup> three‐weekly paclitaxel for platinum pre‐treated epithelial ovarian cancer. In eight studies examining 175 mg/m<sup>2</sup> from 1997 to 2016, 21 participants experienced grade 3 or 4 neurotoxicity out of a total of 435 participants (4.8%) (<a href="#CD008766-tbl-0008">Table 5</a>). In contrast, in four studies examining ≥ 200 mg/m<sup>2</sup> paclitaxel from 1996 to 2002, 37 participants out of a total of 234 experienced grade 3 or 4 neurotoxicity (15.8%) (<a href="#CD008766-tbl-0008">Table 5</a>). There was a significant difference between these groups (P &lt; 0.0001, <a href="#CD008766-tbl-0008">Table 5</a>). </p> <div class="table" id="CD008766-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Neurotoxicity: 175 mg/m2 or ≥ 200 mg/m2 three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of 3‐weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3 or 4 neurotoxicity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0032" title="EzcurdiaL , JovtisSL , MickiewiczE , TemperleyG , RondinonM , BlajmanC , et al, Argentine Multicenter Taxol group. Paclitaxel in platinum-resistant ovarian cancer patients.. Seminars in Oncology1997;24(5 Suppl 15):S15.">Ezcurdia 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0048" title="IshikawaH , NakanishiT , NawaA , SuzukiY , KuzuyaK . 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. International Journal of Clinical Oncology2001;6(3):128-31.">Ishikawa 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0074" title="OliverioG , CanutiD , TononiA , ScarpelliniM , PanziniI , GalliI , et al. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients. Journal of Chemotherapy1999;11(4):301-5.">Oliverio 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0078" title="PectasidesD , PapadopoulouM , VarthalitisJ , MylonakisA , KostopoulouM , DimitriadisM , et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology1998;55(3):228-34.">Pectasides 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0016" title="PiccartMJ , GreenJA , LacaveAJ , ReedN , VergoteI , Benedetti-PaniciP , et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology group. Journal of Clinical Oncology2000;18(6):1193-202. ">Piccart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0090" title="Ten Bokkel HuininkW , GoreM , CarmichaelJ , GordonA , MalfetanoJ , HudsonI , et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology1997;15(6):2183-93.">Ten Bokkel Huinink 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0019" title="TropeC , HogbergT , KaernJ , BertelsenK , BjorkholmE , BomanK , et al. Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Annals of Oncology1998;9(12):1301-7. ">Trope 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>435</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>21 (4.8</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0100" title="WilailakS , TresukosolD , LinasmitaV , TermrungruanglertW . Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer. European Journal of Gynaecological Oncology2000;21(6):610-2.">Wilailak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0073" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1996;23(3):317-25.">Noda 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0057" title="KudelkaA , VerschraegenC , ShenY , De LeonC , EdwardsC , FreedmanR , et al. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. International Journal of Gynaecological Cancer1999;9(1):44-53.">Kudelka 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>234</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37 (15.8</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Fishers Exact Test:</b> P &lt; 0.0001 </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008766-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD008766-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008766-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-FIG-03" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD008766-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Weekly Paclitaxel versus Three‐Weekly Paclitaxel, outcome: 1.1 Overall Survival." data-id="CD008766-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Weekly Paclitaxel versus Three‐Weekly Paclitaxel, outcome: 1.1 Overall Survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.2 Response rate" data-id="CD008766-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.2 Response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.3 Progression‐free survival" data-id="CD008766-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.3 Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.4 Neurotoxicity." data-id="CD008766-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.4 Neurotoxicity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.5 Neutropenia" data-id="CD008766-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Weekly paclitaxel versus three‐weekly paclitaxel, outcome: 1.5 Neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 175 mg/m2 paclitaxel versus 250 mg/m2 paclitaxel, outcome: 2.2 Response rate" data-id="CD008766-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 175 mg/m<sup>2</sup> paclitaxel versus 250 mg/m<sup>2</sup> paclitaxel, outcome: 2.2 Response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 1: Overall survival" data-id="CD008766-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 2: Response rate" data-id="CD008766-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 2: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 3: Progression‐free survival" data-id="CD008766-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 3: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 4: Neurotoxicity" data-id="CD008766-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 4: Neurotoxicity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 5: Neutropenia" data-id="CD008766-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 5: Neutropenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 6: Alopecia" data-id="CD008766-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 6: Alopecia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0016"> <p> <div class="table" id="CD008766-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Quality of life (QoL)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 3</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 4</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 5</b> </p> </th> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel versus 3‐weekly paclitaxel, Outcome 7: Quality of life (QoL) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0016">Navigate to figure in review</a></div> </div> <div class="figure" id="CD008766-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 175 mg/m2 paclitaxel versus 250 mg/m2 paclitaxel, Outcome 1: Overall survival" data-id="CD008766-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: 175 mg/m<sup>2</sup> paclitaxel versus 250 mg/m<sup>2</sup> paclitaxel, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 175 mg/m2 paclitaxel versus 250 mg/m2 paclitaxel, Outcome 2: Response rate" data-id="CD008766-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: 175 mg/m<sup>2</sup> paclitaxel versus 250 mg/m<sup>2</sup> paclitaxel, Outcome 2: Response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 175 mg/m2 paclitaxel versus 250 mg/m2 paclitaxel, Outcome 3: Progression‐free survival" data-id="CD008766-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: 175 mg/m<sup>2</sup> paclitaxel versus 250 mg/m<sup>2</sup> paclitaxel, Outcome 3: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 175 mg/m2 paclitaxel versus 250 mg/m2 paclitaxel, Outcome 4: Neurotoxicity" data-id="CD008766-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: 175 mg/m<sup>2</sup> paclitaxel versus 250 mg/m<sup>2</sup> paclitaxel, Outcome 4: Neurotoxicity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 175 mg/m2 paclitaxel versus 250 mg/m2 paclitaxel, Outcome 5: Neutropenia" data-id="CD008766-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: 175 mg/m<sup>2</sup> paclitaxel versus 250 mg/m<sup>2</sup> paclitaxel, Outcome 5: Neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0022"> <p> <div class="table" id="CD008766-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Alopecia</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 3</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 4</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 5</b> </p> </th> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: 175 mg/m<sup>2</sup> paclitaxel versus 250 mg/m<sup>2</sup> paclitaxel, Outcome 6: Alopecia </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0022">Navigate to figure in review</a></div> </div> <div class="figure" id="CD008766-fig-0023"> <p> <div class="table" id="CD008766-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Quality of life (QoL)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 3</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 4</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 5</b> </p> </th> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: 175 mg/m<sup>2</sup> paclitaxel versus 250 mg/m<sup>2</sup> paclitaxel, Outcome 7: Quality of life (QoL) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0023">Navigate to figure in review</a></div> </div> <div class="figure" id="CD008766-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: 135 mg/m2 paclitaxel versus 175 mg/m2 paclitaxel, Outcome 1: Overall survival" data-id="CD008766-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: 135 mg/m<sup>2</sup> paclitaxel versus 175 mg/m<sup>2</sup> paclitaxel, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: 135 mg/m2 paclitaxel versus 175 mg/m2 paclitaxel, Outcome 2: Response rate" data-id="CD008766-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: 135 mg/m<sup>2</sup> paclitaxel versus 175 mg/m<sup>2</sup> paclitaxel, Outcome 2: Response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: 135 mg/m2 paclitaxel versus 175 mg/m2 paclitaxel, Outcome 3: Progression‐free survival" data-id="CD008766-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: 135 mg/m<sup>2</sup> paclitaxel versus 175 mg/m<sup>2</sup> paclitaxel, Outcome 3: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/urn:x-wiley:14651858:media:CD008766:CD008766-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: 135 mg/m2 paclitaxel versus 175 mg/m2 paclitaxel, Outcome 4: Neurotoxicity" data-id="CD008766-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_t/tCD008766-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: 135 mg/m<sup>2</sup> paclitaxel versus 175 mg/m<sup>2</sup> paclitaxel, Outcome 4: Neurotoxicity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/media/CDSR/CD008766/image_n/nCD008766-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008766-fig-0028"> <p> <div class="table" id="CD008766-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Neutropenia</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 3</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 4</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 5</b> </p> </th> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: 135 mg/m<sup>2</sup> paclitaxel versus 175 mg/m<sup>2</sup> paclitaxel, Outcome 5: Neutropenia </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0028">Navigate to figure in review</a></div> </div> <div class="figure" id="CD008766-fig-0029"> <p> <div class="table" id="CD008766-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Alopecia</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 3</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 4</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 5</b> </p> </th> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: 135 mg/m<sup>2</sup> paclitaxel versus 175 mg/m<sup>2</sup> paclitaxel, Outcome 6: Alopecia </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0029">Navigate to figure in review</a></div> </div> <div class="figure" id="CD008766-fig-0030"> <p> <div class="table" id="CD008766-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Quality of life</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 3</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 4</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 5</b> </p> </th> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: 135 mg/m<sup>2</sup> paclitaxel versus 175 mg/m<sup>2</sup> paclitaxel, Outcome 7: Quality of life </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-fig-0030">Navigate to figure in review</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008766-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Weekly paclitaxel compared to three‐weekly paclitaxel for the treatment of recurrent epithelial ovarian cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Weekly paclitaxel compared to three‐weekly paclitaxel for the treatment of recurrent epithelial ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with recurrent epithelial ovarian cancer<br/><b>Setting:</b> hospital or clinic<br/><b>Intervention:</b> weekly paclitaxel<br/><b>Comparison:</b> three‐weekly paclitaxel </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with three‐weekly paclitaxel</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with weekly paclitaxel</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival<br/>follow‐up: mean 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.94<br/>(0.66 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>263<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may have little to no effect on overall survival but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 100<br/>(63 to 87) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/>(0.78 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>263<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may have little to no effect on response rate but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 100<br/>(26 to 49) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate ‐ platinum‐sensitive</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/>(0.77 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may have little to no effect on response rate in platinum‐sensitive disease but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 100<br/>(37 to 79) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate ‐ platinum‐resistant</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.55 to 2.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>163<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may have little to no effect on response rate in platinum‐resistant disease but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 100<br/>(12 to 47) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of Life ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival<br/>follow‐up: mean 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.83<br/>(0.46 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>263<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,</sup><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may have little to no effect on progression‐free survival but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 100<br/>(100 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurotoxicity</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.53<br/>(0.19 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>260<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may have little to no effect on neurotoxicity but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 100<br/>(5 to 38) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neutropenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.51<br/>(0.27 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>260<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may result in a reduction in neutropenia.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 100<br/>(11 to 38) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Alopecia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.58<br/>(0.46 to 0.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>205<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel may result in a reduction in alopecia.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 100<br/>(36 to 58) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 3 levels for extremely serious imprecision (fewer than 300 events, fewer than 5 studies and the 95% CI included both appreciable benefit and appreciable harm) </p> <p><sup>2</sup> Downgraded 1 level for inconsistency (moderate heterogeneity between the 2 included studies. Possibly due to taxane pre‐treatment status) </p> <p><sup>3</sup> Downgraded 2 levels for very serious imprecision (fewer than 300 events, and fewer than 5 studies) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Weekly paclitaxel compared to three‐weekly paclitaxel for the treatment of recurrent epithelial ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008766-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">175 mg/m2 paclitaxel compared to 250 mg/m2 paclitaxel for the treatment of recurrent epithelial ovarian cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>175 mg/m<sup>2</sup> paclitaxel compared to 250 mg/m<sup>2</sup> paclitaxel for the treatment of recurrent epithelial ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with recurrent epithelial ovarian cancer<br/><b>Setting:</b> hospital or clinic<br/><b>Intervention:</b> 175 mg/m<sup>2</sup> paclitaxel<br/><b>Comparison:</b> 250 mg/m<sup>2</sup> paclitaxel </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 250 mg/m<sup>2</sup> paclitaxel</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 175 mg/m<sup>2</sup> paclitaxel</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival<br/>follow‐up: mean 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.97<br/>(0.77 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel may result in little to no difference in overall survival. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 100<br/>(77 to 90) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.40 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>265<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel may have little to no effect on response rate but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 100<br/>(15 to 69) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate ‐ platinum‐sensitive</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.60<br/>(0.39 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>213<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel may result in a reduction in response rate in platinum‐sensitive disease. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 100<br/>(14 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate ‐ platinum‐resistant</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.34<br/>(0.70 to 2.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel may have little to no effect on response rate in platinum‐resistant disease but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 100<br/>(25 to 93) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of Life ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival<br/>follow‐up: mean 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.07<br/>(0.88 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel may result in little to no difference in progression‐free survival. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>96 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 100<br/>(94 to 98) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurotoxicity</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.41<br/>(0.21 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel probably reduces neurotoxicity. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 100<br/>(3 to 13) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neutropenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/>(0.74 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175 mg/m<sup>2</sup> paclitaxel may result in little to no difference in neutropenia. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 100<br/>(14 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alopecia ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 2 levels for serious imprecision (fewer than 5 studies and 95% CI included both appreciable benefit and appreciable harm) </p> <p><sup>2</sup> Downgraded 3 levels for very serious imprecision (fewer than 300 events, fewer than 5 studies and 95% CI included both appreciable benefit and appreciable harm) </p> <p><sup>3</sup> Downgraded 2 levels for serious imprecision (fewer than 300 events, fewer than 5 studies) </p> <p><sup>4</sup> Downgraded 1 level for imprecision (fewer than 5 studies) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">175 mg/m2 paclitaxel compared to 250 mg/m2 paclitaxel for the treatment of recurrent epithelial ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008766-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">135 mg/m2 paclitaxel compared to 175 mg/m2 paclitaxel for the treatment of recurrent epithelial ovarian cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>135 mg/m<sup>2</sup> paclitaxel compared to 175 mg/m<sup>2</sup> paclitaxel for the treatment of recurrent epithelial ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with recurrent epithelial ovarian cancer<br/><b>Setting:</b> hospital or clinic<br/><b>Intervention:</b> 135 mg/m<sup>2</sup> paclitaxel<br/><b>Comparison:</b> 175 mg/m<sup>2</sup> paclitaxel </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 175 mg/m<sup>2</sup> paclitaxel</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 135 mg/m<sup>2</sup> paclitaxel</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival<br/>follow‐up: mean 15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.96<br/>(0.77 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>407<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>135 mg/m<sup>2</sup> paclitaxel may result in little to no difference in overall survival. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 100<br/>(65 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.48 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>382<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>135 mg/m<sup>2</sup> paclitaxel may result in little to no difference in response rate. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 100<br/>(9 to 23) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of Life ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival<br/>follow‐up: mean 15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.09<br/>(0.94 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>407<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>135 mg/m<sup>2</sup> paclitaxel may result in little to no difference in progression‐free survival. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 100<br/>(93 to 97) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurotoxicity</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.19<br/>(0.01 to 3.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>391<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>135 mg/m<sup>2</sup> paclitaxel may result in little to no difference in neurotoxicity. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(0 to 42) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutropenia ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alopecia ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 2 levels for very serious imprecision (fewer than 5 studies, 95% CI included both appreciable benefit and appreciable harm) </p> <p><sup>2</sup> Downgraded 3 levels for extremely serious imprecision (fewer than 300 events, fewer than 5 studies and 95% CI included both appreciable benefit and appreciable harm) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">135 mg/m2 paclitaxel compared to 175 mg/m2 paclitaxel for the treatment of recurrent epithelial ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008766-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overall and progression‐free survival: weekly or three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of 3‐weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0022" title="BruzzoneM , CatsafadosE , MigliettaL , AmorosoD , PedullaF , GiannessiPG , et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology1996;53(5):349-53.">Bruzzone 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0007" title="Du BoisA , LuckHJ , BuserK , MeerpohlHG , SessaC , KlaassenU , et al. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. European Journal of Cancer1997;33(3):379-84. ">Du Bois 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0039" title="GoreME , LevyV , RustinG , PerrenT , CalvertAH , EarlH , et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. British Journal of Cancer1995;72(4):1016-9.">Gore 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0046" title="HoekmanK , HuijskesRV , BurgerCW , VerheijenRH , PinedoHM , VermorkenJB . [Favorable results of paclitaxel (taxol) in patients with ovary carcinoma pretreated with platinum] [Dutch]. Nederlands Tijdschrift voor Geneeskunde1995;139(6):272-8.">Hoekman 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0079" title="PhillipsKA , FriedlanderM , OlverI , EvansB , SmithJ , FitzharrisB , et al. Australasian multicentre phase II study of paclitaxel (taxol) in relapsed ovarian cancer. Australian and New Zealand Journal of Medicine1995;25(4):337-43.">Phillips 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0093" title="TrimbleEL , AdamsJD , VenaD , HawkinsMJ , FriedmanMA , FishermanJS , et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. Journal of Clinical Oncology1993;11(12):2405-10.">Trimble 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0091" title="ThigpenJT , BlessingJA , BallH , HummelSJ , BarrettRJ . Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of Clinical Oncology1994;12(9):1748-53.">Thigpen 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0005" title="CantuMG , BudaA , ParmaG , RossiR , FlorianiI , BonazziC ,  et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. Journal of Clinical Oncology2002;20(5):1232-7. ">Cantu 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0032" title="EzcurdiaL , JovtisSL , MickiewiczE , TemperleyG , RondinonM , BlajmanC , et al, Argentine Multicenter Taxol group. Paclitaxel in platinum-resistant ovarian cancer patients.. Seminars in Oncology1997;24(5 Suppl 15):S15.">Ezcurdia 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0044" title="HernadiZ , HugaS , LukacskoL , KrasznaiZ , SapyT . Chemotherapy resistance of ovarian cancer patients after platinum-based therapy paclitaxel as a choice of treatment. [Hungarian]. Magyar Noorvosok Lapja2001;64(3):249-54.">Hernadi 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0048" title="IshikawaH , NakanishiT , NawaA , SuzukiY , KuzuyaK . 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. International Journal of Clinical Oncology2001;6(3):128-31.">Ishikawa 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0074" title="OliverioG , CanutiD , TononiA , ScarpelliniM , PanziniI , GalliI , et al. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients. Journal of Chemotherapy1999;11(4):301-5.">Oliverio 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0078" title="PectasidesD , PapadopoulouM , VarthalitisJ , MylonakisA , KostopoulouM , DimitriadisM , et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology1998;55(3):228-34.">Pectasides 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0016" title="PiccartMJ , GreenJA , LacaveAJ , ReedN , VergoteI , Benedetti-PaniciP , et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology group. Journal of Clinical Oncology2000;18(6):1193-202. ">Piccart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0081" title="PlannerRS , AllenDG , BrandAH , GrantPT , TonerGC , SykesPH . Paclitaxel (taxol) as salvage therapy for relapsed ovarian cancer. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(2):168-70.">Planner 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0090" title="Ten Bokkel HuininkW , GoreM , CarmichaelJ , GordonA , MalfetanoJ , HudsonI , et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology1997;15(6):2183-93.">Ten Bokkel Huinink 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0019" title="TropeC , HogbergT , KaernJ , BertelsenK , BjorkholmE , BomanK , et al. Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Annals of Oncology1998;9(12):1301-7. ">Trope 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0100" title="WilailakS , TresukosolD , LinasmitaV , TermrungruanglertW . Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer. European Journal of Gynaecological Oncology2000;21(6):610-2.">Wilailak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0055" title="KohnEC , SarosyG , BicherA , LinkC , ChristianM , SteinbergSM , et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. Journal of the National Cancer Institute1994;86(1):18-24.">Kohn 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0057" title="KudelkaA , VerschraegenC , ShenY , De LeonC , EdwardsC , FreedmanR , et al. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. International Journal of Gynaecological Cancer1999;9(1):44-53.">Kudelka 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PFS weighted mean ± SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OS weighted mean ± SD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.68 ± 1.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.50 ± 3.51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>175 mg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.85 ± 2.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.34 ± 5.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 mg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.39 ± 0.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>P value 175</b> versus <b>250 mg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.283</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0059" title="LeT , HopkinsL , BainesKA , RamboutL , Al HaykiM , Kee FungMF . Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecologic Oncology2006;102(1):49-53.">Le 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60‐80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0030" title="DunderI , BerkerB , AtabekogluC , BilginT . Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. European Journal of Gynaecological Oncology2005;26(1):79-82.">Dunder 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0052" title="KaernJ , BaekelandtM , TropéCG . A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. European Journal of Gynaecological Oncology2002;23(5):383-9.">Kaern 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0056" title="KristensenG , KaernJ , BaekelandtM , Skeie-JensensenT , De Pont ChristensenR , Avall-LundqvistE , et al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: a NSGO study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings)2008;26(Suppl):Abstract.">Kristensen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0062" title="LortholaryA , LargillierR , WeberB , GladieffL , AlexandreJ , DurandoX , et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Annals of Oncology2012;23(2):346-52.">Lortholary 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0011" title="MarkmanM , HallJ , SpitzD , WeinerS , CarsonL , Van LeL , et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. Journal of Clinical Oncology2002;20(9):2365-9. ">Markman 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0063" title="MarkmanM , BlessingJ , RubinSC , ConnorJ , HanjaniP , WaggonerS . Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecologic Oncology2006;101(3):436-40.">Markman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PFS weighted mean ± SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OS weighted mean ± SD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>All studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.38 ± 1.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.92 ± 1.63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>P value weekly</b> versus <b>3‐weekly</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.207</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ND: Not Determined<br/>NR: Not Reported<br/>SD: Standard Deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overall and progression‐free survival: weekly or three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008766-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Response rate: weekly or three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3‐weekly paclitaxel study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose of 3‐weekly</b> </p> <p><b>paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete or partial response</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0064" title="McGuireWP , RowinskyEK , RosensheinNB , GrumbineFC , EttingerDS , ArmstrongDK , et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Annals of Internal.Medicine1989;111(4):273-9.">McGuire 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110‐250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0093" title="TrimbleEL , AdamsJD , VenaD , HawkinsMJ , FriedmanMA , FishermanJS , et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. Journal of Clinical Oncology1993;11(12):2405-10.">Trimble 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0022" title="BruzzoneM , CatsafadosE , MigliettaL , AmorosoD , PedullaF , GiannessiPG , et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology1996;53(5):349-53.">Bruzzone 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0007" title="Du BoisA , LuckHJ , BuserK , MeerpohlHG , SessaC , KlaassenU , et al. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. European Journal of Cancer1997;33(3):379-84. ">Du Bois 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0039" title="GoreME , LevyV , RustinG , PerrenT , CalvertAH , EarlH , et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. British Journal of Cancer1995;72(4):1016-9.">Gore 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0046" title="HoekmanK , HuijskesRV , BurgerCW , VerheijenRH , PinedoHM , VermorkenJB . [Favorable results of paclitaxel (taxol) in patients with ovary carcinoma pretreated with platinum] [Dutch]. Nederlands Tijdschrift voor Geneeskunde1995;139(6):272-8.">Hoekman 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0057" title="KudelkaA , VerschraegenC , ShenY , De LeonC , EdwardsC , FreedmanR , et al. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. International Journal of Gynaecological Cancer1999;9(1):44-53.">Kudelka 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0014" title="NardiM , AloeA , De MarcoS , CognettiF , IacovelliA , AtlanteG , et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. American Journal of Clinical Oncology1997;20(3):230-2. ">Nardi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0079" title="PhillipsKA , FriedlanderM , OlverI , EvansB , SmithJ , FitzharrisB , et al. Australasian multicentre phase II study of paclitaxel (taxol) in relapsed ovarian cancer. Australian and New Zealand Journal of Medicine1995;25(4):337-43.">Phillips 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0040" title="GoreME , PrestonN , A'HernRP , HillC , MitchellP , ChangJ , et al. Platinum-taxol non-cross resistance in epithelial ovarian cancer. British Journal of Cancer1995;71(6):1308-10.">Gore 1995a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0001" title="EisenhauerE , BaconM , WalshW , McDanielC , CanettaR , OnettoN , et al. Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). In: European Cancer Conference; 1997. 1997:Abstract 532. EisenhauerEA , Ten Bokkel HuininkWW , SwenertonKD , GianniL , MylesJ , Van der BurgME , et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology1994;12(12):2654-66. [DOI: 10.1200/jco.1994.12.12.2654]Ten Bokkel HuininkWW , EisenhauerE , SwenertonK , Canadian-European Taxol Cooperative Trial group. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Cancer Treatment Reviews1993;19 Suppl C(Suppl 3):79-86. ">Eisenhauer 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0002" title="OmuraGA , BradyMF , DelmoreJE , LongHJ , LookKY , AveretteE , et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. American Society of Clinical Oncology1996;15:280, Abstract 755. OmuraGA , BradyMF , LookKY , AveretteHE , DelmoreJE , LongHJ , et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. Journal of Clinical Oncology2003;21(15):2843-8. [DOI: 10.1200/JCO.2003.10.082]">Omura 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135‐250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0072" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al, BMS-181339 ovarian cancer study group. [A phase II study of BMS-181339 in patients with ovarian cancer] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1994;21(14):2461-9.">Noda 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0083" title="SarosyG , KohnE , StoneDA , RothenbergM , JacobJ , AdamoDO , et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. Journal of Clinical Oncology1992;10(7):1165-70.">Sarosy 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>170‐300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0005" title="CantuMG , BudaA , ParmaG , RossiR , FlorianiI , BonazziC ,  et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. Journal of Clinical Oncology2002;20(5):1232-7. ">Cantu 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0032" title="EzcurdiaL , JovtisSL , MickiewiczE , TemperleyG , RondinonM , BlajmanC , et al, Argentine Multicenter Taxol group. Paclitaxel in platinum-resistant ovarian cancer patients.. Seminars in Oncology1997;24(5 Suppl 15):S15.">Ezcurdia 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0044" title="HernadiZ , HugaS , LukacskoL , KrasznaiZ , SapyT . Chemotherapy resistance of ovarian cancer patients after platinum-based therapy paclitaxel as a choice of treatment. [Hungarian]. Magyar Noorvosok Lapja2001;64(3):249-54.">Hernadi 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0048" title="IshikawaH , NakanishiT , NawaA , SuzukiY , KuzuyaK . 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. International Journal of Clinical Oncology2001;6(3):128-31.">Ishikawa 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0073" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1996;23(3):317-25.">Noda 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0074" title="OliverioG , CanutiD , TononiA , ScarpelliniM , PanziniI , GalliI , et al. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients. Journal of Chemotherapy1999;11(4):301-5.">Oliverio 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0078" title="PectasidesD , PapadopoulouM , VarthalitisJ , MylonakisA , KostopoulouM , DimitriadisM , et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology1998;55(3):228-34.">Pectasides 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0016" title="PiccartMJ , GreenJA , LacaveAJ , ReedN , VergoteI , Benedetti-PaniciP , et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology group. Journal of Clinical Oncology2000;18(6):1193-202. ">Piccart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0081" title="PlannerRS , AllenDG , BrandAH , GrantPT , TonerGC , SykesPH . Paclitaxel (taxol) as salvage therapy for relapsed ovarian cancer. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(2):168-70.">Planner 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0090" title="Ten Bokkel HuininkW , GoreM , CarmichaelJ , GordonA , MalfetanoJ , HudsonI , et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology1997;15(6):2183-93.">Ten Bokkel Huinink 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0091" title="ThigpenJT , BlessingJA , BallH , HummelSJ , BarrettRJ . Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of Clinical Oncology1994;12(9):1748-53.">Thigpen 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0019" title="TropeC , HogbergT , KaernJ , BertelsenK , BjorkholmE , BomanK , et al. Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Annals of Oncology1998;9(12):1301-7. ">Trope 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0100" title="WilailakS , TresukosolD , LinasmitaV , TermrungruanglertW . Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer. European Journal of Gynaecological Oncology2000;21(6):610-2.">Wilailak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0055" title="KohnEC , SarosyG , BicherA , LinkC , ChristianM , SteinbergSM , et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. Journal of the National Cancer Institute1994;86(1):18-24.">Kohn 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2633</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>651 (24.7</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weekly paclitaxel study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete or partial response</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0033" title="FennellyD , AghajanianC , ShapiroF , O'FlahertyC , McKenzieM , O'ConnorC , et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. Journal of Clinical Oncology1997;15(1):187-92.">Fennelly 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40‐100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0059" title="LeT , HopkinsL , BainesKA , RamboutL , Al HaykiM , Kee FungMF . Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecologic Oncology2006;102(1):49-53.">Le 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60‐80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0021" title="AnderssonH , HorvathG , MellqvistL , WestbergR . Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot study. International Journal of Gynecological Cancer1997;7(4):262-6.">Andersson 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67‐81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0089" title="TakanoM , KikuchiY , KitaT , SuzukiM , OhwadaM , YamamotoT , et al. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer. Anticancer Research2002;22(3):1833-8.">Takano 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70‐100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0030" title="DunderI , BerkerB , AtabekogluC , BilginT . Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. European Journal of Gynaecological Oncology2005;26(1):79-82.">Dunder 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0036" title="GhamandeS , LeleS , MarchettiD , BakerT , OdunsiK . Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. International Journal of Gynecological Cancer2003;13(2):142-7.">Ghamande 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0052" title="KaernJ , BaekelandtM , TropéCG . A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. European Journal of Gynaecological Oncology2002;23(5):383-9.">Kaern 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0054" title="KitaT , KikuchiY , TakanoM , SuzukiM , OowadaM , KonnoR , et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecologic Oncology2004;92(3):813-8.">Kita 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0056" title="KristensenG , KaernJ , BaekelandtM , Skeie-JensensenT , De Pont ChristensenR , Avall-LundqvistE , et al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: a NSGO study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings)2008;26(Suppl):Abstract.">Kristensen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0062" title="LortholaryA , LargillierR , WeberB , GladieffL , AlexandreJ , DurandoX , et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Annals of Oncology2012;23(2):346-52.">Lortholary 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0011" title="MarkmanM , HallJ , SpitzD , WeinerS , CarsonL , Van LeL , et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. Journal of Clinical Oncology2002;20(9):2365-9. ">Markman 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0063" title="MarkmanM , BlessingJ , RubinSC , ConnorJ , HanjaniP , WaggonerS . Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecologic Oncology2006;101(3):436-40.">Markman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>471</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>169 (35.9</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Fishers Exact Test:</b> P = 0.0002 </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Response rate: weekly or three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008766-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Neutropenia: weekly or three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of 3‐weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3 or 4 neutropenia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0022" title="BruzzoneM , CatsafadosE , MigliettaL , AmorosoD , PedullaF , GiannessiPG , et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology1996;53(5):349-53.">Bruzzone 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0039" title="GoreME , LevyV , RustinG , PerrenT , CalvertAH , EarlH , et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. British Journal of Cancer1995;72(4):1016-9.">Gore 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0046" title="HoekmanK , HuijskesRV , BurgerCW , VerheijenRH , PinedoHM , VermorkenJB . [Favorable results of paclitaxel (taxol) in patients with ovary carcinoma pretreated with platinum] [Dutch]. Nederlands Tijdschrift voor Geneeskunde1995;139(6):272-8.">Hoekman 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0014" title="NardiM , AloeA , De MarcoS , CognettiF , IacovelliA , AtlanteG , et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. American Journal of Clinical Oncology1997;20(3):230-2. ">Nardi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0079" title="PhillipsKA , FriedlanderM , OlverI , EvansB , SmithJ , FitzharrisB , et al. Australasian multicentre phase II study of paclitaxel (taxol) in relapsed ovarian cancer. Australian and New Zealand Journal of Medicine1995;25(4):337-43.">Phillips 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0072" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al, BMS-181339 ovarian cancer study group. [A phase II study of BMS-181339 in patients with ovarian cancer] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1994;21(14):2461-9.">Noda 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0091" title="ThigpenJT , BlessingJA , BallH , HummelSJ , BarrettRJ . Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of Clinical Oncology1994;12(9):1748-53.">Thigpen 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0005" title="CantuMG , BudaA , ParmaG , RossiR , FlorianiI , BonazziC ,  et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. Journal of Clinical Oncology2002;20(5):1232-7. ">Cantu 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0032" title="EzcurdiaL , JovtisSL , MickiewiczE , TemperleyG , RondinonM , BlajmanC , et al, Argentine Multicenter Taxol group. Paclitaxel in platinum-resistant ovarian cancer patients.. Seminars in Oncology1997;24(5 Suppl 15):S15.">Ezcurdia 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0048" title="IshikawaH , NakanishiT , NawaA , SuzukiY , KuzuyaK . 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. International Journal of Clinical Oncology2001;6(3):128-31.">Ishikawa 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0074" title="OliverioG , CanutiD , TononiA , ScarpelliniM , PanziniI , GalliI , et al. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients. Journal of Chemotherapy1999;11(4):301-5.">Oliverio 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0078" title="PectasidesD , PapadopoulouM , VarthalitisJ , MylonakisA , KostopoulouM , DimitriadisM , et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology1998;55(3):228-34.">Pectasides 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0016" title="PiccartMJ , GreenJA , LacaveAJ , ReedN , VergoteI , Benedetti-PaniciP , et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology group. Journal of Clinical Oncology2000;18(6):1193-202. ">Piccart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0081" title="PlannerRS , AllenDG , BrandAH , GrantPT , TonerGC , SykesPH . Paclitaxel (taxol) as salvage therapy for relapsed ovarian cancer. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(2):168-70.">Planner 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0090" title="Ten Bokkel HuininkW , GoreM , CarmichaelJ , GordonA , MalfetanoJ , HudsonI , et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology1997;15(6):2183-93.">Ten Bokkel Huinink 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0019" title="TropeC , HogbergT , KaernJ , BertelsenK , BjorkholmE , BomanK , et al. Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Annals of Oncology1998;9(12):1301-7. ">Trope 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0073" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1996;23(3):317-25.">Noda 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0057" title="KudelkaA , VerschraegenC , ShenY , De LeonC , EdwardsC , FreedmanR , et al. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. International Journal of Gynaecological Cancer1999;9(1):44-53.">Kudelka 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1052</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>544 (51.7</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3 or 4 neutropenia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0021" title="AnderssonH , HorvathG , MellqvistL , WestbergR . Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot study. International Journal of Gynecological Cancer1997;7(4):262-6.">Andersson 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67‐81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0089" title="TakanoM , KikuchiY , KitaT , SuzukiM , OhwadaM , YamamotoT , et al. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer. Anticancer Research2002;22(3):1833-8.">Takano 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70‐100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0030" title="DunderI , BerkerB , AtabekogluC , BilginT . Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. European Journal of Gynaecological Oncology2005;26(1):79-82.">Dunder 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0036" title="GhamandeS , LeleS , MarchettiD , BakerT , OdunsiK . Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. International Journal of Gynecological Cancer2003;13(2):142-7.">Ghamande 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0052" title="KaernJ , BaekelandtM , TropéCG . A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. European Journal of Gynaecological Oncology2002;23(5):383-9.">Kaern 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0054" title="KitaT , KikuchiY , TakanoM , SuzukiM , OowadaM , KonnoR , et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecologic Oncology2004;92(3):813-8.">Kita 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0062" title="LortholaryA , LargillierR , WeberB , GladieffL , AlexandreJ , DurandoX , et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Annals of Oncology2012;23(2):346-52.">Lortholary 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0011" title="MarkmanM , HallJ , SpitzD , WeinerS , CarsonL , Van LeL , et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. Journal of Clinical Oncology2002;20(9):2365-9. ">Markman 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0063" title="MarkmanM , BlessingJ , RubinSC , ConnorJ , HanjaniP , WaggonerS . Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecologic Oncology2006;101(3):436-40.">Markman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0080" title="PignataS , LorussoD , ScambiaG , SambataroD , TamberiS , CinieriS , et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncology2015;16(5):561-8.">Pignata 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>402</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>35 (8.7</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Fishers Exact Test:</b> P &lt; 0.0001 </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Neutropenia: weekly or three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008766-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Alopecia: weekly or three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of 3‐weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3 or 4 alopecia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0022" title="BruzzoneM , CatsafadosE , MigliettaL , AmorosoD , PedullaF , GiannessiPG , et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology1996;53(5):349-53.">Bruzzone 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0039" title="GoreME , LevyV , RustinG , PerrenT , CalvertAH , EarlH , et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. British Journal of Cancer1995;72(4):1016-9.">Gore 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0014" title="NardiM , AloeA , De MarcoS , CognettiF , IacovelliA , AtlanteG , et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. American Journal of Clinical Oncology1997;20(3):230-2. ">Nardi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0079" title="PhillipsKA , FriedlanderM , OlverI , EvansB , SmithJ , FitzharrisB , et al. Australasian multicentre phase II study of paclitaxel (taxol) in relapsed ovarian cancer. Australian and New Zealand Journal of Medicine1995;25(4):337-43.">Phillips 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135‐175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0072" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al, BMS-181339 ovarian cancer study group. [A phase II study of BMS-181339 in patients with ovarian cancer] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1994;21(14):2461-9.">Noda 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0091" title="ThigpenJT , BlessingJA , BallH , HummelSJ , BarrettRJ . Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of Clinical Oncology1994;12(9):1748-53.">Thigpen 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0032" title="EzcurdiaL , JovtisSL , MickiewiczE , TemperleyG , RondinonM , BlajmanC , et al, Argentine Multicenter Taxol group. Paclitaxel in platinum-resistant ovarian cancer patients.. Seminars in Oncology1997;24(5 Suppl 15):S15.">Ezcurdia 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0048" title="IshikawaH , NakanishiT , NawaA , SuzukiY , KuzuyaK . 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. International Journal of Clinical Oncology2001;6(3):128-31.">Ishikawa 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0078" title="PectasidesD , PapadopoulouM , VarthalitisJ , MylonakisA , KostopoulouM , DimitriadisM , et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology1998;55(3):228-34.">Pectasides 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0090" title="Ten Bokkel HuininkW , GoreM , CarmichaelJ , GordonA , MalfetanoJ , HudsonI , et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology1997;15(6):2183-93.">Ten Bokkel Huinink 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0019" title="TropeC , HogbergT , KaernJ , BertelsenK , BjorkholmE , BomanK , et al. Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Annals of Oncology1998;9(12):1301-7. ">Trope 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0100" title="WilailakS , TresukosolD , LinasmitaV , TermrungruanglertW . Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer. European Journal of Gynaecological Oncology2000;21(6):610-2.">Wilailak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0073" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1996;23(3):317-25.">Noda 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0057" title="KudelkaA , VerschraegenC , ShenY , De LeonC , EdwardsC , FreedmanR , et al. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. International Journal of Gynaecological Cancer1999;9(1):44-53.">Kudelka 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>878</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>445 (50.1</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3 or 4 alopecia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0021" title="AnderssonH , HorvathG , MellqvistL , WestbergR . Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot study. International Journal of Gynecological Cancer1997;7(4):262-6.">Andersson 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67‐81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0089" title="TakanoM , KikuchiY , KitaT , SuzukiM , OhwadaM , YamamotoT , et al. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer. Anticancer Research2002;22(3):1833-8.">Takano 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70‐100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0030" title="DunderI , BerkerB , AtabekogluC , BilginT . Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. European Journal of Gynaecological Oncology2005;26(1):79-82.">Dunder 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0052" title="KaernJ , BaekelandtM , TropéCG . A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. European Journal of Gynaecological Oncology2002;23(5):383-9.">Kaern 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0054" title="KitaT , KikuchiY , TakanoM , SuzukiM , OowadaM , KonnoR , et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecologic Oncology2004;92(3):813-8.">Kita 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0062" title="LortholaryA , LargillierR , WeberB , GladieffL , AlexandreJ , DurandoX , et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Annals of Oncology2012;23(2):346-52.">Lortholary 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0080" title="PignataS , LorussoD , ScambiaG , SambataroD , TamberiS , CinieriS , et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncology2015;16(5):561-8.">Pignata 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>267</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 (3.7</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Fishers Exact Test:</b> P &lt; 0.0001 </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Alopecia: weekly or three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008766-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Neurotoxicity: 175 mg/m2 or ≥ 200 mg/m2 three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose of 3‐weekly paclitaxel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3 or 4 neurotoxicity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0032" title="EzcurdiaL , JovtisSL , MickiewiczE , TemperleyG , RondinonM , BlajmanC , et al, Argentine Multicenter Taxol group. Paclitaxel in platinum-resistant ovarian cancer patients.. Seminars in Oncology1997;24(5 Suppl 15):S15.">Ezcurdia 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0048" title="IshikawaH , NakanishiT , NawaA , SuzukiY , KuzuyaK . 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. International Journal of Clinical Oncology2001;6(3):128-31.">Ishikawa 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0074" title="OliverioG , CanutiD , TononiA , ScarpelliniM , PanziniI , GalliI , et al. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients. Journal of Chemotherapy1999;11(4):301-5.">Oliverio 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0003" title="OsmanMA , ElkadyMS , NasrKE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clinical Medicine Insights: Oncology2016;10:35-41. ">Osman 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0078" title="PectasidesD , PapadopoulouM , VarthalitisJ , MylonakisA , KostopoulouM , DimitriadisM , et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology1998;55(3):228-34.">Pectasides 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0016" title="PiccartMJ , GreenJA , LacaveAJ , ReedN , VergoteI , Benedetti-PaniciP , et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology group. Journal of Clinical Oncology2000;18(6):1193-202. ">Piccart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0090" title="Ten Bokkel HuininkW , GoreM , CarmichaelJ , GordonA , MalfetanoJ , HudsonI , et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology1997;15(6):2183-93.">Ten Bokkel Huinink 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0019" title="TropeC , HogbergT , KaernJ , BertelsenK , BjorkholmE , BomanK , et al. Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Annals of Oncology1998;9(12):1301-7. ">Trope 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>435</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>21 (4.8</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008766-bbs2-0004" title="AnderssonH , BomanK , RidderheimP , RosenbergP , SorbeU , PuistolaU . An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. In: American Society of Clinical Oncology; 2000. 2000. RosenbergP , AnderssonH , BomanK , RidderheimM , SorbeB , PuistolaU , et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncologica (Stockholm, Sweden)2002;41(5 CNO):418-24. ">Rosenberg 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0100" title="WilailakS , TresukosolD , LinasmitaV , TermrungruanglertW . Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer. European Journal of Gynaecological Oncology2000;21(6):610-2.">Wilailak 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0073" title="NodaK , IkedaM , KudoR , NishiyaI , YajimaA , TanakaK , et al. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion] [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]1996;23(3):317-25.">Noda 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008766-bbs2-0057" title="KudelkaA , VerschraegenC , ShenY , De LeonC , EdwardsC , FreedmanR , et al. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. International Journal of Gynaecological Cancer1999;9(1):44-53.">Kudelka 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>234</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37 (15.8</b> %<b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Fishers Exact Test:</b> P &lt; 0.0001 </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Neurotoxicity: 175 mg/m2 or ≥ 200 mg/m2 three‐weekly paclitaxel single‐arm studies in platinum pre‐treated recurrent ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/full#CD008766-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008766-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Weekly paclitaxel versus 3‐weekly paclitaxel</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.66, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.78, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Platinum‐sensitive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.77, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Platinum‐resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.48, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.46, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Neurotoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.19, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.27, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Alopecia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.46, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Quality of life (QoL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Weekly paclitaxel versus 3‐weekly paclitaxel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008766-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">175 mg/m2 paclitaxel versus 250 mg/m2 paclitaxel</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.77, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.40, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Platinum‐sensitive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.39, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Platinum‐resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.70, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.88, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Neurotoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.21, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.74, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Alopecia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Quality of life (QoL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">175 mg/m2 paclitaxel versus 250 mg/m2 paclitaxel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008766-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">135 mg/m2 paclitaxel versus 175 mg/m2 paclitaxel</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.77, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.48, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.94, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Neurotoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 3.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Alopecia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">135 mg/m2 paclitaxel versus 175 mg/m2 paclitaxel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008766.pub3/references#CD008766-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008766.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008766-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008766-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008766-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008766-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD008766-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD008766-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD008766-note-0009">Português</a> </li> <li class="section-language"> <a class="" href="th#CD008766-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008766-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008766-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008766\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008766\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008766\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008766\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008766\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008766.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008766.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008766.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008766.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008766.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729720419"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008766.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729720422"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008766.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee3c92d5f9377',t:'MTc0MDcyOTcyMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 